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Diabetes mellitus (DM) has become an epidemic and is estimated to affect 366 
million people worldwide by 2030. In particular, the prevailing type 2 diabetes 
mellitus is a chronic disease that can hardly be cured. Current treatment includes 
lifestyle intervention and medications like oral hypoglycemic agents. Common oral 
hypoglycemic agents have different adverse effects like nausea and vomiting for 
metformin, hypoglycemia for sulphonylureas and unwanted weight gain and even 
potential heart or liver failure for thiazolidinedione. Investigation for alternative 
hypoglycemic agents with fewer side effects is needed. In this project, the effect of 
berberine, an isoquinoline alkaloid extracted from Tradition Chinese Medicine 
Coptis chinensis or Huanglian, on glucose control in obese, diabetic db/db mice was 
investigated, with special interest on the proteomic alterations in visceral adipose 
tissues of berberine-treated db/db mice. Berberine treatment led to loss of body 
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weight in db/db mice by 25.33%. The average fasting blood glucose level of 
berberine-treated mice was 266.80mg/dL, compared with 466.83mgAlL of that of 
control mice. Glucose-lowering ability of db/db mice was also slightly improved 
after berberine treatment. Berberine could also inhibit triglyceride accumulation in 
3T3-L1 adipocytes. However, it inhibited lipolysis in 3T3-L1 adipocytes in short-
term (24h) treatment but enhanced lipolysis during prolonged (72h) treatment. 
Proteomic study with 2D gel electrophoresis and mass spectrometry revealed 
increase in glycolysis, lipolysis and beta-oxidation and inhibition of TCA cycle and 
oxidative phosphorylation in visceral adipose tissue of berberine-treated db/db mice 
and berberine-treated 3T3-L1 adipocytes. ER stress-related proteins were also up-
regulated after treatment. Western blotting confirmed that berberine activated AMPK 













引起的蛋白質組改變°黃連素對3 T 3 - L 1脂肪細胞的影響也在硏究範圍之內。 
服用黃連素使 d b / d b小鼠的體重減輕了 25.33% ’處理組的平均空腹血糖值為 
2 6 6 . 8 0 m g / d L，而對照組的數值為 4 6 6 . 8 3 m g / d L �黃連素亦能輕微改善 d b / d b小 




及 3 T 3 - L 1脂肪細胞中能增加醣酵解、脂肪分解� b e t a-氧化作用’同時能抑制 
棒檬酸循環、氧化隣酸化作用。黃連素也增加了脂肪細胞中內質網壓力相關蛋 




I would like to express my sincere gratitude to my supervisors, Prof. Ngai Sai Ming 
and Prof. Cheng Hon Ki, for their patient guidance and valuable advice in my project 
and my thesis. Furthermore, I would like to extend my sincere gratitude to other 
members of my thesis committee, Prof. Ge Wei, Prof. Au Wing Ngor Shannon and 
Prof. Wan Man Fan Jennifer for their valuable suggestions, advices and comments of 
my thesis. I am also grateful for the support provided by Prof. Fung Ming Chiu 
during the extended period of my graduate study. 
Special thanks go to our laboratory technician Ms. Tsai Sau Na for her professional 
technical support and helpful assistance since I was an undergraduate. My 
appreciation goes to Ms Wang Chun Mei and Ms Wong Ngan Yuk for teaching me 
animal tissue culture techniques. 
I would like to thank all my labmates in EG08 and G95 for their valuable 
suggestions, encouragement, emotional support, assistance throughout my whole 
course of study and for their kindness and consideration when I was expecting. 
Finally, I would like to thank my husband for his love and wholehearted support and 
encouragement. I would also like to thank my parents for taking care of my baby 
daughter when I was preparing my thesis and oral examination. 
vi 
Table of Content 
Thesis/ Assessment Committee i 
Declaration ii 
Acknowledgments vi 
Table ofContent vii 
List ofAbbreviations x 
List ofFigures xiv 
List ofTables xv 
1. Literature Review 1 
1.1 Introduction of diabetes mellitus 1 
1.1.1 Definition and prevalence 1 
1 • 1 1 Diagnosis and classification 2 
1.1.3 Symptoms and complications 4 
1.1.4 Cause and risk factors 5 
1.1 • 5 Prevention and treatment 9 
1.2 The role of adipose tissue in pathophysiology of T2DM 10 
1.2.1 Randle's glucose-fatty acid hypothesis 11 
1.2.2 Ectopic fat storage hypothesis 12 
1.2.3 Adipose tissue as an endocrine organ 13 
1.2.4 Low-grade inflammation 15 
1.2.5 Endoplasmic reticulum (ER) stress 17 
1.3 Use of berberine in the treatment of T2DM 18 
1.3.1 Efficacy of berberine in treating diabetes 18 
1.3.2 Berberine on glucose and lipid metabolism of animals 19 
1.3.3 Inhibition of adipogenesis 20 
1.3.4 Activation of AMP-Activated Protein Kinase (AMPK) 20 
1.3.5 Mitochondrial inhibition 21 
1.4 Introduction of proteomics 21 
1.4.1 Why proteomics? 22 
1.4.2 Gel-based proteomics: Two-Dimensional Gel Electrophoresis 23 
1.4.3 Gel-free proteomics 25 
1.4.4 Mass spectrometry 26 
1.4.5 Proteomics as tool for diabetes research 27 
vii 
1.5 Obj ectives and significance 32 
2. Materials and Methods 34 
2.1 Drug preparation 34 
2.2 Animal experiment 34 
2.3 Comparison of proteome of visceral white adipose tissue: obese db/db mice vs 
lean m+/db mice and BBR-treated vs control db/db mice 36 
2.3.1 Protein sample preparation from adipose tissue 36 
2.3.2 Protein quantitation 37 
2.3.3 2D Gel electrophoresis 37 
2.3.4 Image analysis 39 
2.3.5 In-gel digestion and MALDI-ToF MS 39 
2.4 Cell culture experiment 40 
2.5 Oil Red 0 staining 42 
2.6 Glycerol determination 42 
2.7 Comparison of proteomes of BBR-treated and control 3T3-L1 adipocytes .•…43 
2.7.1 Protein sample preparation from 3T3-L1 cells 43 
2.7.2 Protein quantitation 43 
2.7.3 2D Gel electrophoresis 44 
2.7.4 Image analysis 44 
2.7.5 In-gel digestion and MALDI-ToF MS 44 
2.8 Western Immunoblotting 44 
2.8.1 Protein sample preparation of BBR-treated and control 3T3-L1 44 
2.8.2 SDS-PAGE 44 
2.8.3 Protein blotting 45 
2.8.4 Membrane blocking and antibody incubations 45 
2.8.5 Detection of Proteins 46 
2.9 Statistical analysis 46 
3. Results 47 
3.1 Comparison of total protein profiles of visceral adipose tissue of obese db/db 
and lean m+/db mice 47 
3.2 Effect of berberine on glucose metabolism of obese db/db mice 53 
3.3 Comparison of the protein profiles of visceral adipose tissue of BBR-treated 
and control db/db mice 55 
3.4 Effect of berberine treatment on 3T3-L1 adipocytes 61 
3.4.1 Berberine treatment inhibited intracellular triglyceride accumulation in both 
mature and pre-mature 3T3-L1 adipocytes 61 
3.4.2 Berberine treatment enhanced lipolysis in mature 3T3-L1 adipocytes but 
inhibited lipolysis in pre-mature 3T3-L1 adipocytes 65 
viii 
3.4.3 Color change in culture media after berberine treatment 65 
. 3.4.4. Comparison of protein profiles between berberine-treated and control 3T3-L1 
adipocytes 67 
3.4.5 Western blotting 73 
4. Discussion 75 
4.1 Comparison of total protein profiles of visceral adipose tissue of obese db/db 
and lean m+/db mice 75 
4.2 Berberine lowers body weight, reduces fasting blood glucose level and 
improves glucose-lowering ability of db/db mice 78 
4.3 Comparison of the protein profiles of visceral adipose tissue of BBR-treated 
and control db/db mice 79 
4.4 Berberine inhibited lipid accumulation in mature and pre-mature 3T3-L1 
adipocytes 84 
4.5 Berberine enhanced lipolysis in mature 3T3-L1 adipocytes but inhibited 
lipolysis in pre-mature 3T3-L1 adipocytes 84 
4.6 Comparison of the protein profiles of BBR-treated and control 3T3-L1 
adipocytes 85 
4.7 Western blotting 88 
4.8 General discussion 89 
5. References 92 
ix 
List of Abbreviations 
^ig Micro gram 
2-DE Two-Dimensional Gel Electrophoresis 
2D Two dimensional 
2D-DIGE Two-dimensional fluorescence difference gel analysis technology 
A2MG Alpha-2-Macroglobulin 
ACN Acetonitrile 
ADA Amercian Diabetes Association 
AMP 5' Adenosine Monophosphate 
AMPK 5' Adenosine Monophosphate-activated Protein Kinase 
ANAX1 Annexin A1 
aP2 Adipocyte Protein 2 
AR Aldose Reductase 
ATM Adipose Tissue Macrophage 
ATP Adenosine 5-triphosphate . 
BACH2 Basic leucine zipper transcription factor 2 
BBR Berberine Hydrochloride 
BSA Bovine serum albumin 
C.I.% Confidence interval % C/EBP CCAAT-Enhancer-Binding Protein 
CD36 - Cluster ofDifferentiation 36 
CHAPS 3 - [(3-Cholamidopropyl)dimethylammonio] -1 -propanesulfonate 
CLEC16 C-type lectin domain family 16，member A 
CO2 Carbon dioxide 
CoA Coenzyme A 
COFRADIC Combined Fractional Diagonal Chromatography 
CTLA4 Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) 
Ctrl — Control 
DAG Diacylglycerol 
dL Deciliter 
DM Diabetes Mellitus 
DMEM Dulbecco Modified Eagle Medium 
DMSO “ Dimethyl Sulfoxide 
DNA Deoxyribonucleic Acid 
dpi Dots per inch 
DTT Dithiothreitol 
EDTA Ethylenediamine-tetraacetic acid 
ER Endoplasmic Reticulum 
ERK Extracellular signal-regulated kinases 
ESI Electrospray Ionization 
FBG Fasting Blood Glucose 
FBS Fetal Bovine Serum 
FFA Free Fatty Acid 
xii 
_g Gram 
Gal-3 Galectin-3 “ 
GDM Gestational Diabetes Mellitus 
GIIS Glucose-induced Insuiln Secretion 
GLUT4 Glucose Transporter Type 4 
GRP Glucose-Responsive Protein 
J^ Hour 
HbAlc Glycated Haemoglobin 
HC1 Hydrogen chloride 
HC1 Hydrochloric acid / Hydrochloride 
HFD - High-Fat Diet 
HIF Hypoxia-Inducible Factor 
HLA Human leukocyte antigen 
hnRNP Heterogeneous nuclear ribonucleoprotein 
HPLC High performance liquid chromatography 
hr Hour 
HSP90 Heat shock 90kDa protein 
ICAT — Isotope-Coded Affinity Tag •_ 
IEF Isoelectric focusing 
IFG Impaired Fasting Glucose 
IGT Impaired Glucose Tolerance 
IKK(3 - IkB kinase p 
IL Interleukin 
IL-2 Interleukin-2 
IL2RA Interleukin 2 receptor, alpha 
mS — Insulin 
IPG Immobilized pH Gradient 
IRS Insulin Receptor Substrate 
JNK c-Jun N-terminal kinase 
kDa — Kilodalton 
kg Kilogram 
_L Liter 
LDL Low-density Lipoprotein 
MALDI Matrix-Assisted Laser Desorption / Ionization 
MALDI- ToF Matrix-assisted laser desorption ionization - time of flight 
MAPK1 Mitogen Activated Protein Kinase 1 
MCP-1 Monocyte Chemotactic Protein-1 
meter M 
min Minute 
mL Milli liter 
mm Milli meter 
mM Milli molar 
mRNA Messenger ribonucleic acid 
MS Mass Spectrometry 
MTT 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide 
MudPIT Multidimensional Protein Identification Technology 
xi 
MW Molecular weight 
NaCl Sodium chloride 
NAD+ Nicotinamide Adenine Dinucleotide 
NADP+ Nicotinamide Adenine Dinucleotide Phosphate 
NEFA Non-esterified Fatty Acid 
NFkB Nuclear Factor Kappa-light-chain-enhancer 
nm Nano meter 
OGTT 一 Oral Glucose Tolerance Test 
PAGE Polyacrylamide gel electrophoresis 
PAI-1 Plasminogen Activator Inhibitor 
PBG Postprandial Blood Glucose 
PBS Phosphate buffer saline 
PDI Protein disulphide isomerase 
pI Isoelectric point 
PI3K Phosphatidylinositol 3-kinase 
PMF Peptide Mass Fingerprint 
PPAR Peroxisome proliferator-activated receptor 
PTPN2 Protein tyrosine phosphate, non-receptor type 2 . 
PTPN22 Protein tyrosine phosphate, non-receptor type 22 
PVDF Polyvinylidene Fluoride 
ROS Reactive Oxygen Species 
rpm Revolutions per minute 
SDS Sodium dodecyl sulfate 
SELDI Surface-Enhanced Laser Desorption/Ionization 
SGA Small for Gestational Age 
SNP Single Nucleotide Polymorphism 
SREBP-1 c Sterol regulatory element binding protein-1 c 
STZ Streptozotocin 
TlDM Type 1 Diabetes Mellitus 
T2DM 一 Type 2 Diabetes Mellitus 
TAP1 Antigen peptide transporter 1 
TBST Tris buffer saline with Tween-20 
TCA Trichloroacetic acid 
TCA cycle Citric Acid Cycle 
TFA Trifluoroacetic acid 
TG Triglyceride 
TLR4 — Toll-like Receptor 4 
TNF Tumor necrosis factor 
Tris Tris(hydroxymethyl)aminomethane 
UBASH3A Ubiquitin-associated and SH3 domain-containing protein A 
UPR Unfolded Protein Response 
UV - Ultraviolet 
_V Voltage 一 
V ‘ Volt ‘ 
v/v Volume per volume 
VAT Visceral Adipose Tissue 
xii 
Vhr Voltage hour 
VLDL Very low-density lipoprotein 
VNTR Variable Number ofTandem Repeats 
w/v Weight per volume 
WAT White Adipose Tissue 
WHO — World Health Organization 
P-cell Beta cells 
i^L Micro liter 
xiii 
List of Figures 
Fig. 3.1a 2D gel pattem of visceral adipose tissue of obese db/db mice 48 
Fig. 3.1b 2D gel pattem of visceral adipose tissue oflean m+/db mice 49 
Fig. 3.2.1 Body weight of BBR-treated mice dropped more drastically than that of 
control db/db mice 53 
Fig. 3.2.2 Berberine treatment resulted in a lower fasting blood glucose level in 
db/db mice 54 
Fig. 3.2.3 Mild improvement in glucose-lowering effect was resulted after 
berberine treatment_ 54 
Fig. 3.3a 2D gel pattem of visceral adipose tissue ofBBR-treated db/db mice... 56 
Fig. 3.3b 2D gel pattem of visceral adipose tissue of control db/db mice 57 
Fig. 3.4.1.1 Berberine inhibited intracellular lipid accumulation in mature 3T3-L1 
adipocytes 62 
Fig. 3.4.1.2 Berberine inhibited intracellular lipid accumulation in pre-mature 3T3-L1 
adipocytes 63 
Fig. 3.4.1.3 Mature 3T3-L1 adipocytes stained with Oil Red 0 Staining 
(magnification, X100) 64 
Fig. 3.4.2.1 Glycerol concentration of culture media from mature 3T3-L1 adipocytes 
increased after berberine treatment for 72h 65 
Fig.3.4.2.2 Glycerol concentration of culture media from pre-mature 3T3-L1 
adipocytes decreased after treated with 5p,M berberine for 24h 65 
Fig. 3.4a 2D gel pattem of mature 3T3-L1 adipocytes treated with 5 i^M berberine 
for 72h 68 
Fig. 3.4b 2D gel pattem of control mature 3T3-L1 adipocytes 69 
Fig. 3.4.5.1 Berberine treatment enhanced the activation of AMPK-alpha in mature 
3T3-L1 adipocytes 73 
Fig. 3.4.5.2 Berberine treatment inhibited SAPK/JNK activity in mature 3T3-L1 
adipocytes 73 
Fig. 3.4.5.3 Berberine treatment increased PDI expression but did not alter the 
expression of adiponectin in mature 3T3-L1 adipocytes 74 
xiv 
List ofTables 
Table 1.1 Diagnostic criteria of different glucose tolerance status according to the 
WHO and the ADA 3 
Table 1.2 Some candidate loci/genes linked to TlDM 1 
Table 3.1 Proteins of differential abundance between visceral adipose tissue of obese 
db/db mice and that oflean m+/db mice 48 
Table 3.3 Proteins of differential abundance between visceral adipose tissue of 
BBR-treated db/db mice and that of control db/db mice 56 
Table 3.4 Proteins of differential abundance between BBR-treated and control 3T3-L1 
adipocytes 68 
XV 
1. Literature Review 
1.1 Introduction of diabetes mellitus 
1.1.1 Definition and prevalence 
Diabetes mellitus (DM) is a group of metabolic disorders marked by high levels of 
blood glucose resulting from defects in insulin secretion, insulin action or both 
(Alberti et al., 1998). It is associated with reduced life expectancy, significant 
morbidity, increased risk of cardiovascular complications (ischaemic heart disease, 
stroke and peripheral vascular disease), and diminished quality of life (World Health 
Organization, 2006). 
Recent estimates indicate there were 171 million people worldwide suffering from 
diabetes in 2000 and this was projected to increase to 366 million by 2030 (Wild et 
al., 2004). Prevalence of diagnosed and undiagnosed diabetes in the United States in 
2007 was estimated to be 23.6 million people or 7.8% of the population of all ages, 
of which 5.7 million people were undiagnosed (Centers for Disease Control and 
Prevention, 2007). The American Diabetes Association (ADA) estimated that the 
national costs of diabetes in the USA for 2002 was US$132 billion, and the figure 
would increase to US$192 billion in 2020 (American Diabetes Association, 2003). In 
Hong Kong, it is estimated that about 10% of the population is suffering from 
diabetes (Diabetes Hong Kong, http://www.diabetes-hk.orgV A recent review 
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reported that the percentage of undiagnosed diabetes in Hong 
Kong and Taiwan combined is 52.6% (Wong et al., 2006). 
1.1.2 Diagnosis and classification 
Criteria for diagnosis of diabetes and other stages of glucose tolerance have been 
changed considerably over the last 20 years (National Diabetes Data Group, 1979; 
World Health Organization, 2006). There are a number of important differences 
between the ADA and the WHO recommendations which may lead to differences in 
an individual's classification of glucose tolerance. The ADA adopts fasting plasma 
glucose as the recommended method for diagnosing asymptomatic diabetes by the 
ADA while the WHO recommends the oral glucose tolerance test (OGTT), which 
was discouraged by the ADA in clinical practice for its "inconvenience, less 
reproducibility, greater cost" (The Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus, 2003). The fasting plasma glucose (FPG) value 
used to define impaired fasting glucose (IFG) also differs. The ADA defmes IFG 
with FPG of 5.6-6.9 mmol/1 whereas the defining value ofFPG recommended by the 
WHO ranges from 6.1 to 6.9 mmol/1. Table 1.1 shows the criteria for classification 
of glucose tolerance status recommended by the WHO and the ADA. It should be 
noted that individuals with IFG and/or impaired glucose tolerance (IGT) are 
described as having "prediabetes", which “is a not clinical entity but rather a risk 
factor for future diabetes and adverse outcomes" (World Health Organization, 2006). 
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“ WH0 1999 ADA 2003 
Diabetes Fasting plasma >7.0 mmol/1 >7.0 mmol/l 
mellitus glucose* 
(DM) or or 
2-h plasma > 11.1 mmol/1 > 11.1 mmol/l 
glucose** 
Impaired Fasting plasma <7.0 mmol/1 Not required 
glucose glucose* (ifmeasured) 
tolerance and 
(IGT) 2-h plasma 7.8 to 11.0 mmol/1 7.8 to 11.0 mmol/1 
glucose** 
Impaired Fasting plasma 6.1 to 6.9 mmol/1 5.6 to 6.9mmol/l 
fasting glucose* 
glucose and 
(IFG) 2-h plasma <7.8 mmol/1 Measurement not 
glucose** (Measurement recommended) recommended 
Table 1 • 1 Diagnostic criteria of different glucose tolerance status according to 
the WHO andtheADA. 
*Fasting is defined as no caloric intake for at least 8h. **Value should be obtained 
during an OGTT performed as described by the WHO, using a glucose load 
containing the equivalent of 75g anhydrous glucose dissolved in water. Source: 
Alberti et al., 1998; The Expert Committee on the Diagnosis and Classification of 
Diabetes Mellitus, 2003. 
Diabetes mellitus is classified into different etiological types according to the 
defects，disorders or processes leading to the development ofdiabetes mellitus. There 
are four main types of diabetes: type 1 diabetes mellitus, type 2 diabetes mellitus, 
other specific types and gestational diabetes mellitus. 
Type 1 diabetes mellitus (TlDM), previously known as insulin-dependent diabetes 
mellitus or juvenile-onset diabetes mellitus, develops from autoimmune destruction 
of pancreatic p-cells, leading to absolute insulin deficiency. This form of diabetes 
accounts for only 5-10% of all diagnosed cases of diabetes in adults (Centers for 
Disease Control and Prevention, 2007). The rate of p-cell destruction and the 
progression to ketoacidosis are variable. TlDM is fatal and patients must undergo' 
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insulin treatment for survival. There is currently no clinically useful preventive 
measure against the development ofTlDM. 
Type 2 diabetes mellitus (T2DM), previously referred to as non-insulin-dependent 
diabetes mellitus or adult-onset diabetes mellitus, results from insulin resistance and 
relative insulin deficiency. It accounts for about 90-95% of all diagnosed cases of 
diabetes. Patients of T2DM do not need insulin treatment for survival, at least 
initially, and ketoacidosis seldom develops spontaneously in T2DM (American 
Diabetes Association, 2009). 
Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance 
with onset or first recognition during pregnancy. Prevalence of GDM may range 
from 1 to 14% of all pregnancies, depending on the population studied and the 
diagnostic tests employed (American Diabetes Association, 2004). If untreated, 
GDM increases the risk of macrosomia (baby being too large for gestational age) of 
infants (HAPO Study Cooperative Research Group, 2008). Neonates are also at an 
increased risk of hypoglycemia, jaundice, high red blood cell mass (polycythemia) 
and low blood calcium (hypocalcemia) and magnesium (hypomagnesemia) (Jones, 
2001). 
1.1.3 Symptoms and complications 
Beside hyperglycemia, classic symptoms of diabetes include frequent urination 
(polyuria) and increased thirst (polydipsia). TlDM patients may also experience 
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blurred vision, frequent hunger, unusual weight loss and extreme fatigue and 
irritability (Alberti et al., 1998). All these symptoms may also appear on T2DM 
patients, though much more slowly and subtle, except significant weight loss. In 
severe cases, ketoacidosis or a non-ketotic hyperosmolar state may develop and lead 
to stupor, coma and even death. Often symptoms are not severe, or may be absent, 
and consequently long-term hyperglycemia may be sufficient to cause pathological 
and functional changes before diagnosis is made. Long-term DM may lead to 
progressive development of the specific complications of retinopathy with potential 
blindness, nephropathy that may lead to renal failure, and/or neuropathy with risk of 
foot ulcers, amputation, Charcot joints, and features of autonomic dysfunction, 
including erectile dysfunction. People with diabetes are also at increased risk of 
cardiovascular, peripheral vascular and cerebrovascular disease (Alberti et al., 1998). 
1.1.4 Cause and risk factors 
TlDM is an autoimmune disorder in which the insulin-producing pancreatic p-cells 
are subject to the attack of the host immune system. To date, the cause o fT lDM is 
still not fully understood but both genetic and environmental factors should be taken 
into account. The lifetime risk of TlDM of an individual in a general population is 
quoted as 0.4% (Mehers et al., 2008) whereas the sibling risk is 6%, 15 times higher 
than one in a general population (Risch, 1987). In a population study in Finland, the 
concordance rates ofTlDM in monozygotic twins and dizygotic twins were 27% and 
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3.8% respectively (Hyttinen et al., 2003)，indicating the importance of environmental 
factors in the trigger ofTlDM in genetically susceptible individuals. Studies of the 
environmental factors and genetic-environmental interactions involved in the 
development of TlDM are ongoing, with specific emphasis on diets, infections, 
gestational events and even socioeconomic factors (The Environmental Determinants 
ofDiabetes in the Young, http://teddy.epi.usf.edu). 
Different strategies have been used in attempt to identify TlDM susceptibility genes. 
In 1970s, association between TlDM and human leukocyte antigen (HLA) class II 
on chromosome 6p21.3 (IDDM1) was shown (Thomsen et al., 1975). It is now 
considered that HLA-mediated susceptibility represents 50% of the genetic 
susceptibility to TlD (Ounissi-Benkalha et al., 2008). The second locus found to be 
associated with TlDM, IDDM2, is a variable number of tandem repeat region in the 
promoter of the INS gene (insulin) (Bell et al., 1984; Bennett et al., 1995). 
Advancement in technology makes whole genome screens possible in 1990s. Areas 
of the genome linked to TlD were assigned IDDM numbers and IDDM 1-18 have 
been allocated to various regions of the genome (Mehers et al., 2008). However, not 
all loci's association with TlDM was reproducible in larger scale genome wide 
association studies which operate at a much higher level of statistical power 
(Concannon et al., 2009; Grant et al., 2009). Table 1.2 summarizes some known 
loci/genes associated with TlDM. 
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Locus Gene Function Allele(s)/SNP(s)AVNTRs linked 
toTlDM 
Chromosome Human leukocyte Regulation of HLA class II DQB1*0302 on 
6p21.3 antigen (HLA) immume the DR4 haplotype and 
(IDDM 1) system DQB1 *0201 on the DR3 
haplotype 
(DR2-DQBl*0602 is 
protective) Chromosome Insulin (INS) Insulin Short VNTR class I. 
11P15.5 production (Longer class III are protective) 
(IDDM2) 
Chromosome Cytotoxic T- Negative SNP rs3087243 
2q33 (IDDM12) lymphocyte- regulation of 
associated protein 4 T-cell 
(CTLA4) activation 
Chromosome Protein tyrosine Regulation of SNPC1858T; 
lpl3 phosphate, non- T-cell SNP rs2488457 C-G 
receptor type 22 activation 
(PTPN22) • 
Chromosome Interleukin 2 Binding of SNP ss52580101,C-A; 
10pl5.1 receptor, alpha interleukin 2 SNP rsll594656, T-A 
(IDDM 10) (IL2RA) / CD25 for regulation 
ofT-cell 
proliferation 
Chromosome C-t>^e lectin domain Cell surface SNP rsl2708716, A-G; 
16pl3.2 family 16，member A receptor in SNP rs725613, A-C; 
(CLEC16)/ immune cells SNP rsl7673553, A-G; 
KIAA0350 SNP rs2903692, A-G 
Chromosome Basic leucine zipper Acting as SNP rs3757247 
6ql5 transcription factor 2 transcriptional 
(BACH2) activator or 
repressor 
Chromosome Ubiquitin-associated Regulation of SNP rs9976767 
21q22.3 and SH3 domain- T-cell 
containing protein A activation 
(UBASH3A) 
Chromosome Protein tyrosine Regulation of SNP rsl893217; 
18pll.3-pll.2 phosphate, non- cytokine- SNP rs478582 ’ 
receptor type 2 induced 
(PTPN2) pancreatic p-
cells apoptosis 
Table 1.2 Some candidate loci/genes linked to TlDM. 
Abbreviations: SNP-single nucleotide polymorphism; VNTR-variable numbers of 
tandem repeats 
Source from Bottini et al , 2004; Kawasaki et al., 2007; Wellcome Trust Case 
Control Consortium, 2007; Hakonarson et al, 2007; Grant et al., 2009; Todd et al.， 
2007. 
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T2DM arises as a result of insulin resistance of the body. It is a multifactorial disease 
and the etiology and molecular basis of insulin resistance is still unknown. Common 
risk factors of T2DM include prior glucose intolerance (IGT andy'or IFG), prior 
gestational diabetes, family history of type 2 diabetes, hyperinsulinemia, history of 
dyslipidemia, obesity and/or central obesity, sedentary lifestyle, high-fat diet, history 
ofhypertension, low birth weight and so on. 
Hu et al. carried out a 16-year study following up the diets, lifestyle and development 
ofT2DM of about 85000 female nurses (Hu et al., 2001). Obesity was shown to be 
the most important factor. Women with BMI between 30.0 kg/m^ and 34.9 kg/m^ or 
BMI over 35.0 kg/m^ had a 20-fold or 40-fold risk ofbecoming diabetic respectively, 
compared to women whose BMI was below 23.0 kg/m^. Weekly exercise for at least 
7 h per week reduced the risk of T2DM by 39% compared to those who exercised 
less than 0.5 h per week. Smoking of>14 cigarettes per day increased diabetic risk 
by 39% whereas alcohol intake >lOg/day lowered the risk by 41%. Diet high in 
cereal fiber and polyunsaturated fat and low in saturated and trans fat and glycemic 
load could also reduce the risk ofT2DM. 
A 10-year study involving a cohort of about 40000 Dutch men and women was 
performed to investigate the association of coffee or tea consumption with the risk of 
T2DM. It was found that consumption of at least 3 cups of coffee and/or tea was 
associated with reduced risk of T2DM, and this association could not be explained 
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by blood pressure or intake of magnesium, potassium or caffeine (Van Dieren et al., 
2009). 
There are more and more data supporting the link of being small for gestational age 
(SGA) and rapid infant "catch-up" growth to higher risk of developing T2DM and 
metabolic syndrome (reviewed by Vaag, 2009). The "thrifty phenotype hypothesis" 
or the Barker's Hypothesis states that reduced fetal growth is strongly associated 
with a number of chronic conditions including coronary heart disease, stroke, 
diabetes and hypertension later in life and this increased susceptibility results from 
adaptations of the fetus to in utero environment of limited nutrient supply (Barker, 
1997). Other studies also showed that fast postnatal "catch-up" growth may have 
adverse effects on the metabolic health of SGA babies. The potential state of cellular 
hunger in SGA infants at birth may facilitate a more efficient nutritional uptake and 
energy metabolism and therefore a higher postnatal growth rate. However, 
breastfeeding for 3-6 months is associated with reduced risk ofT2DM and metabolic 
syndrome (Vaag, 2009). 
1.1.5 Prevention and treatment 
To date, there is no clinically effective measure for preventing TlDM. For the 
prevention of T2DM, lifestyle interventions like having a diet low in saturated fats 
and high in polyunsaturated fats and cereal fibers, regular exercise can reduce the 
long-term risk of developing T2DM and cardiovascular disease (Li et al., 2008; 
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Riserus et al., 2009). Screening high-risk subjects for diabetes allows early detection 
and prompt treatment and thus reduces the progression of diabetes and its 
complications. 
For treatment of TlDM, insulin replacement by injection or insulin pump is 
necessary for survival, together with careful monitoring of blood glucose levels. 
Pancreas or islet cells transplantation is also an alternative therapy. For treating 
T2DM, in addition to medications and self-monitoring of blood glucose levels, 
dietary management and exercises are also important for controlling blood glucose 
level and prevention of complications. 
1.2 The role of adipose tissue in pathophysiology of T2DM 
Obesity is a worldwide epidemic and is one of the most important risk factors of 
T2DM (Hu et al., 2001). It is associated with an increase in adipose tissue mass and 
regional distribution of fat tissue. Adipose tissue has long been regarded as an inert 
storage depot for storing dietary energy in the form of triglycerides within lipid 
droplets in adipocytes. Since the discovery of leptin (Zhang et al., 1994)，more and 
more adipokines have been discovered and the role of adipose tissue as an endocrine 
organ is now well established. Different hypotheses have been suggested in attempt 
to explain the link between obesity and insulin resistance and/or T2DM. The 
"Randle's cycle" introduces the reciprocal relationship between fatty acid oxidation 
10 
and glucose oxidation whereas the "ectopic fat storage hypothesis" suggests that the 
deposition of lipid in insulin-target tissues causes insulin resistance. Other 
hypotheses include secretion of adipokines by adipose tissues, the oxidative stress 
and low-grade inflammatory state of obese adipose tissues and endoplasmic 
reticulum (ER) stress. 
1.2.1 RandIe's glucose-fatty acid hypothesis 
Plasma non-esterified fatty acids (NEFAs) or free fatty acids (FFAs) level is elevated 
in obese individuals. The adipocyte FFA balance of obese individuals remains 
negative even postprandially, i.e. the adipocytes fail to uptake dietary fatty acids and 
keep on releasing NEFA (Frayn et al., 1996). Randle et al. demonstrated that 
enhanced NEFA oxidation inhibited glucose metabolism in body situations with lipid 
excess. It was proposed that the increased plasma NEFAs augmented their cellular 
uptake by mass action and induced their mitochondrial beta-oxidation, winning their 
competition with glucose as energy source. Clinical study demonstrated that NEFAs 
excess impaired insulin action on liver (Ferrannini et al., 1983). The utilization of 
NEFAs might lead to hepatic intracellular accumulation of acetyl-CoA, which 
stimulates gluconeogenesis and glycogenolysis and thus worsening hyperglycemia. It 
was also found that prolonged exposure to NEFAs suppressed glucose-induced 
insulin secretion (GIIS) from pancreatic beta cells (Unger, 1994). The accumulation 
of acetyl-CoA from beta-oxidation within beta cells may block glycolysis, which 
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provides to prerequisite ATP for triggering GIIS. Chronic exposure to NEFA excess 
eventually impairs insulin secretion. Ceramide synthesis due to NEFA utilization 
also affects beta cell function and promotes apoptosis (Unger, 1994). 
1.2.2 Ectopic fat storage hypothesis 
Adipose tissue is the lipid storage depot in our body with buffering effect of dietary 
fat entering the circulation. Adipocytes take up lipids from fat-rich plasma 
lipoproteins with lipoprotein lipase and store triglycerides by lipogenesis under the 
effect of insulin but they can also mobilize the stored fat in the form of NEFAs by 
lipolysis with hormone sensitive lipase when energy is needed elsewhere. In obesity, 
the buffering capacity of adipocytes decreases as the cells are already overloaded 
with triglyceride (Goossens, 2008). The energy surplus is then stored as fat in other 
tissues and organs like liver, skeletal muscles and pancreatic cells (Ravussin et al., 
2002). 
NEFAs from lipolysis of insulin-resistant adipocytes stimulate lipid flux into liver, 
enhance lipogenesis and thus result in increased VLDL secretion and hepatocellular 
lipid accumulation. Glycolysis and beta-oxidation are also enhanced, leading to 
elevation of acetyl-CoA which enters either TCA cycle or ketogensis and generation 
of ROS which leads to mitochondrial dysfunction (Szendroedi et al., 2009). The 
influx of acyl-CoA results in accumulation of signaling intermediates, diacylglycerol 
(DAG) and ceramide, which inhibits insulin signaling in hepatocytes and thus 
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promoting gluconeogenesis even under the presence of insulin. Insulin resistance 
subsequently develops. 
NEFAs cause elevation of acetyl-CoA and mitochondrial dysfunction in myocytes of 
skeletal muscles in a similar way to what they do in hepatocytes. In addition, the 
rising acyl-CoA pool in myocytes also leads to elevated DAG and ceramide, which 
blocks insulin signaling resulting in decreased translocation of the GLUT4 and 
phosphorylation of glucose to glucose-6-phosphate in skeletal muscles. This makes 
the skeletal muscles fail to take up glucose under insulin action and causes insulin 
resistance in skeletal muscles. 
Excessive triglyceride stores in beta cells and adipocyte infiltration of pancreatic 
islets are believed to cause insulin secretion defects in T2DM (Szendroedi et al., 
2009). It is suggested that hormone sensitive lipase in beta cells promotes the 
accumulation of ceramide which causes beta cell apoptosis (Unger, 1994). 
1.2.3 Adipose tissue as an endocrine organ 
Since the discovery of leptin, dozens of adipocyte-secreted factors have been 
identified and more are yet to be discovered. These adipokines have various effects 
and some profoundly affect insulin sensitivtiy and might potentially link obesity with 
T2DM. 
Leptin level increases with fat mass. In neuropeptide Y neurons, it regulates appetites 
by providing a sense of satiety so as to restrict food intake and enhance energy 
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expenditure. In skeletal muscles, leptin stimulates AMPK-mediated reduction of 
ectopic lipid content (Winder, 2001). In hepatocytes, leptin is believed to have 
additive effects with insulin in glycogen storage enhancement and glycogenolysis 
inhibition by which hyperglycemia is prevented (Aiston et al., 1999). However, in 
obesity, leptin's action seems to be selectively disturbed, resulting hyperleptinaemia. 
The central appetite-suppressant effect would be impaired. A direct lipolytic effect of 
hyperleptinaemia on adipocytes was also shown (Martinez et al., 2000). Prolonged 
hyperleptinaemia would induce pancreatic beta cells interleukin (IL)-ip production, 
reducing insulin secretion and enhancing apoptosis ofbeta cells. 
The insulin-sensitizing and anti-inflammatory properties of adiponectin make it a 
"promising" adipokine secreted by adipocytes. The amelioration of insulin resistance 
by adiponectin was found to be AMPK-mediated as adiponectin regulates lipid 
metabolism (increases fuel oxidation and reduces NEFA influx/ectopic fat storage) 
and carbohydrate metabolism (improves hepatic insulin sensitivity and peripheral 
glucose uptake) (Yamauchi et al., 2002). Unfortunately, the circulatory level of 
adiponectin decreases with increasing body mass and visceral fat mass (Weyer et al., 
2001) and adiponectin receptors are markedly down regulated under the state of 
hyperinsulinaemia. It may be due to adipose tissue hypoxia (Hosogai et al., 2007) or 
the action of other adipokines that are overexpressed in obesity, including TNF-a and 
IL-6 (Bmun et al., 2003). 
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Proteins involved in vascular homeostasis, like angiotensinogen and plasminogen 
activator inhibitor (PAI-1), and proteins involved in lipid metabolism, e.g. retinol 
binding protein and cholestertyl ester transfer protein, also belong to adipokines. 
Classical cytokines, like TNF-a, IL-1, IL-6, IL-18, which are associated with 
immunity and inflammation, were also secreted by adipocytes (Trayhum, 2005; 
Badman et al., 2007). 
1.2.4 Low-grade inflammation 
The identification of TNF-a in adipose tissue of experimental animals (Feinstein et 
al., 1993; Hotamisligil et al., 1993) and the discovery of macrophage infiltration in 
adipose tissue in obesity (Weisberg et al., 2003) evidenced the association of 
inflammation and obesity and insulin resistance. A recent report found a remarkable 
shift in the pool of adipose tissue macrophages (ATM) from the altematively-
activated, anti-inflammatory M2 type to the classically-activated, proinflammatory 
Ml type in obese mice due to spatial and temporal differences in the recruitment of 
distinct ATM subtypes (Lumeng et al., 2008). 
Adipose tissue is the site of production of several proinflammatory factors like IL-6 
and monocyte chemotactic protein-1 (MCP-1) (Rotter et al., 2003; Sartipy, P., 2003) 
and the regulation of secretion of these proinflammatory factors by increasing 
adiposity further substantiated the hypothesis of an on-going low-grade inflammation 
during the development of obesity and insulin resistance (Karalis et al., 2009). TNF-
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a, a well-known cytokine involved in inflammatory response, increases IL-6 
production in 3T3-L1 adipocytes (Ruan et al. 2002), inhibits the differentiation of 
human adipocyte precursor cells and 3T3-L1 cells (Petruschke et al., 1993), induces 
apoptosis in human pre-adipocytes and mature adipocytes (Prins et al., 1997)， 
increases lipolysis in human and 3T3-L1 adipocytes and promotes release of free 
fatty acids to the circulation (Zhang et al., 2002), induces insulin-resistance in 
visceral adipocytes by impairing insulin-stimulated glucose uptake and insulin 
signaling at the insulin receptor substrate (IRS)-l/AKT level possibly via activation 
of c-Jun N-terminal kinase (JNK) 1/2 (Fernandez-Veledo et al., 2009) and induces 
peripheral insulin resistance in human in vivo (Plomgaard et al., 2005). IL-6 was also 
found to stimulate lipolysis and fat oxidation in humans (van Hall et al., 2003), to 
inhibit insulin-induced glycogen synthesis in human hepatocytes (Senn et al. 2002) 
and was also suggested to stimulate hepatic production of C-reactive protein 
(Goossens，2008). 
Some signaling pathways linking insulin resistance to inflammation have been 
identified. JNK has been regarded as one of the key signaling molecules involved. 
Elevation of JNK activity was reported in various tissues in T2DM patients and in 
animal models of obesity and diabetes (Hirosumi et al., 2002; Yang et al., 2008). 
Activation of JNK increases serine phosphorylation ofIRS-1 and impairs the insulin 
signaling pathway which involves the activation of the phosphatidylinositol 3-kinase 
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(PI3K pathway). Knockdown of JNK1 in liver of diet-induced-obese mice 
significantly reduces blood glucose and insulin levels and enhances the insulin 
signaling (Yang et al., 2007). Activation of glycolysis, mitochondrial biogenesis, 
fatty acid oxidation, oxidative phosphorylation and TCA cycle was also resulted in 
genome-wide gene expression analysis after knockdown of hepatic JNK1. Another 
important signaling molecule involved is lKB kinase p (IKKP). Activation of IKKp 
causes the induction of NFKB, a transcription factor responsible for upregulation of 
proinflammatory factors. Activation of IKXp/ NPKB and the subsequent induction of 
proinflammatory cytokines can be resulted from binding of free fatty acids to toll-
like receptor 4 (TLR4) (Song et al., 2006). Blocking NpKB in obese mice with 
sodium salicylate could reverse insulin resistance (Yuan et al., 2001). High-dose 
aspirin was found to lower blood glucose in T2DM in clinical observations for many 
years and its effect is now considered to be mediated by the inhibitory effect of 
salicylates on IKKp (Kopp et al., 1994). 
1.2.5 Endoplasmic reticulum (ER) stress 
The ER is the site of triglyceride (TG) droplet formation (Wolins et al., 2006). Under 
cellular stress, unfolded protein response (UPR) would be triggered to cope with the 
misfolded proteins and JNK activation would be resulted, which is linked to 
inhibition of insulin signaling (Gregor et al., 2007). Adipose tissue of obese ob/ob 
mice shows signs of ER stress and UPR activation (Ozcan et al., 2006) accompanied 
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by an increase in JNK activity. Administration of chaperones that block ER stress 
activation was found to reverse insulin resistance (Ozawa et al., 2005; Ozcan et al., 
2006)，making the adipocyte ER another promising therapeutic target for obesity-
and insulin resistance-related pathologies. 
1.3 Use of berberine in the treatment of T2DM 
Berberine is a kind of isoquinoline alkaloids found in plants like Berberis, goldenseal 
{Hydrastis canadensis), and Coptis chinensis, usually in the roots, rhizomes, stems, 
and bark. It is the major bioactive component of Chinese medicine Rhizoma Coptidis 
(Huanglian). As a Traditional Chinese Medicine, the major therapeutic activity of 
Rhizoma Coptidis is for the treatment of infection, diarrhea and inflammation, as 
infectious disease were more popular in ancient China (Yin et al., 2008b). The anti-
diabetic effect of berberine was found when berberine was used to treat diarrhea of 
diabetic patients (Yin et al., 2008b) and it has aroused great interest among 
physicians and researchers. 
1.3.1 Efficacy of berberine in treating diabetes 
There are substantial reports of the use of berberine in the treatment of diabetes in 
Chinese literatures in the past 2 decades O^i, 1988; Xie et al., 2005; Wei et al., 2004). 
For hypoglycemic effect, one clinical study has shown that administration of 
berberine (0.5g, three times a day) reduced fasting blood glucose (FBG) (from 10.6 土 
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0.9 mmol/1 to 6.9 士 0.5 mmol/l), postprandial blood glucose (PBG) (from 19.8 土 1.7 
to 11.1 士 0.9 mmol/1) and HbAlc level by 2 % in adult patients with newly-
diagnosed T2DM (Yin et al., 2008c). Another group reported that daily 
administration of lg berberine for 3 months reduced FBG and PBG from 7.0土0.8 to 
5.6i0.9 mmol/1 and from 12.0i2.7 to 8.9士2.8 mmol/1, HbAlc from 7.5士1.0% to 
6.6±0.7o/o in adult patients newly diagnosed with T2DM. Body weight reduction was 
also observed. Mild to moderate constipation was reported in only 5 out of 60 
patients in berberine-treated group (Zhang et al., 2008). For the effect on lipid 
metabolism, plasma triglyceride decreased from 2.51士2.04 to 1.61士1.10 mmol/1 with 
berberine, total cholesterol decreased from 5.31士0.98 to 4.35土0.96 mmol/1 and LDL-
cholesterol decreased from 3.23±0.81 to 2.55士0.77 mmol/1 while the data from 
placebo group showed no significant changes. It was concluded that berberine is 
effective and safe for treating T2DM and dyslipidaemia (Zhang et al., 2008). 
1.3.2 Berberine on glucose and lipid metabolism of animals 
Berberine was shown to lower weight gain, improve insulin sensitivity and reduce 
blood glucose in both dietary and genetic animal models of T2DM. In obese rats fed 
on a high-fat diet, berberine was reported to lower body weight, FBG, PBG, fasting 
insulin and serum triglyceride level (Yin et al., 2008a; Yin et al., 2004). In T2DM 
rats induced by high-fat diet and low dose of streptozotocin (STZ), berberine 
significantly decreased FBG and improved insulin tolerance (Yin et al., 2004; Leng 
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et al., 2004). In db/db mice, body weight and plasma triglyceride was decreased 
without significant change in food intake and glucose tolerance was improved by 
berberine. Fat mass of berberine-treated mice also decreased, with reduced adipocyte 
size (Lee et al, 2006). Berberine was also reported to restore pancreas damage 
induced by alloxan in Wistar rats (Tang et al., 2006). 
1.3.3 Inhibition of adipogenesis 
Berberine suppresses adipocytes differentiation and reduces lipid accumulation in 
3T3-L1 adipocytes (Lee et al., 2006; Huang et al., 2006; Choi et al., 2006). Berberine 
treatment suppressed the mRNA expression of several lipogenic genes including 
PPARy, C/EBPa, SREBP-lc, fatty acid synthase, acetyl-CoA carboxylase, acyl-CoA 
synthase, lipoprotein lipase, aP2 and CD36. Suppression of PPARy, C/EBPa and 
their upstream regulator, C/EBPp was observed together with inhibition of 3T3-L1 
adipocyte differentiation (Huang et al., 2006). 
1.3.4 Activation of AMP-Activated Protein Kinase (AMPK) 
AMPK is a key regulatory enzyme involved in energy homeostasis. It has been 
suggested to be a potential therapeutic target in the treatment of obesity and T2DM 
(Hwang et al., 2009). Various studies reported that berberine activates AMPK by 
inducing Thr-172 phosphorylation of AMPK in different cells including 3T3-L1 
adipocytes and L6 myotubes and it is believed to be responsible for berberine-
enhanced glycolysis, glucose consumption and glucose uptake (Yin et al., 2008a; Lee 
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et al., 2006; Tumer et al., 2008). It was also suggested that the berberine-induced 
AMPK activation is likely to be the consequence of increased AMP/ATP ratio due to 
mitochondrial inhibition (Yin et al., 2008a). 
1.3.5 Mitochondrial inhibition 
In addition to its anti-diabetic, anti-infection property, berberine was also shown to 
induce cell cycle arrest and apoptosis in several malignant cell lines. Pereira et al. 
showed that berberine is accumulated in the mitochondria of mouse melanoma cell 
line and inhibits oxygen consumption of mitochondria, especially complex I (Pereira 
et al.，2007). Yin et al. suggested that berberine inhibited glucose oxidation in 
mitochondria in 3T3-L1 adipocytes and L6 myotubes as berberine reduced oxygen 
consumption in both types of cells in a dose-dependent manner with an increase in 
lactic acid concentration in culture media (Yin et al, 2008a). Turner et al. also 
showed that berberine inhibits mitochondrial respiratory complex I but not complex 
II in L6 myotubes (Tumer et al., 2008). The mitochondrial inhibitory effect of 
berberine causes an increase in AMP/ATP ratio, which is causally linked to AMPK 
activation. 
1.4 Introduction of proteomics 
The term "proteomics" was coined in 1995 and defined as the large-scale 
characterization and quantitation of "the entire protein complement expressed by a 
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genome, or by a cell or tissue type" (Anderson and Anderson, 1996; Wilkins et al., 
1995). Its goal is to achieve a global and integrated biological view by studying all 
the proteins of a cell or individual rather than one by one individually (Graves and 
Haystead, 2002). Proteomics technology can be divided into two main categories, 
namely expression proteomics and structural and functional proteomics. Expression 
proteomics studies the global protein expression in cells/tissues quantitatively. 
Structural and functional proteomics involves the characterization of protein 
complexes, investigation of structure and function of proteins, protein-protein 
interaction studies, protein polymorphisms and modifications and the study of 
proteins localization in a specific cellular organelle, also known as "cell map" 
(Blackstock et al., 1999; Meri and Baumann, 2001). 
1.4.1 Why proteomics? 
Genome sequencing of many organisms had been completed in the last decade. 
However, genome sequences only tell the static inherited information of an organism 
but not the dynamic gene expression and cell processes in different cells. It is 
generally believed that proteins, but not genes, are responsible for cell phenotypes 
and are the real mediators of physiological functions (Graves and Haystead, 2002; 
Baggerman et al., 2005). To understand when and where certain genes would be 
tumed on, both mRNA expression and protein abundance are of interest. There have 
been extensive studies on mRNA expression using technologies like DNA 
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microarray. However, different studies had shown that there is a poor correlation 
between intracellular mRNA abundance and the respective protein levels in cells 
(Anderson and Seilhamer, 1997; Celis et al., 2000). Thus, mRNA expression should 
not be regarded as a direct reflection of cellular protein content. 
In addition, proteome is far more complex and dynamic than both genome and 
transcriptome, which refers to the total mRNA expression in cells. Many different 
protein isoforms can be formed from one gene as premature mRNA is subject to 
posttranscriptional control like alternative splicing, polyadenylation and mRNA 
editing (Newman, 1998). Translational modifications also regulate the translation of 
mRNA to protein peptides (Jansen et al., 1995). Proteins formed are then subject to 
posttranslational modification. It was estimated that there are up to 200 different 
types ofposttranslational protein modification (Krebs, 1994). Proteins levels are also 
regulated by proteolysis (Kirschner, 1999) and compartmentalization (Colledge and 
Scott, 1999). Wilkins et al. estimated the average number of protein forms per gene 
to be one or two in bacteria, three in yeast, and three or more in human (Wilkins et 
al., 1996). Other group of scientists later estimated that a single mammalian gene can 
encode on average of six different protein species (Dowsey et al., 2003). 
1.4.2 Gel-based proteomics: Two-Dimensional Gel Electrophoresis 
Two-dimensional gel electrophoresis (2-DE), originated in the 70's by 0'Farrell 
(0'Farrell, 1975), is the classical technique for separating proteins in biological 
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samples. Coupled with protein identification by mass spectrometry (MS), 2-DE is 
still the dominating technique of the field as it allows simultaneous separation, 
visualization and quantitation of a large number of proteins in a biological sample at 
one time. 
In the first dimension, proteins are separated according to their isoelectric points on 
an immobilized pH gradient (IPG) (Gorg et al., 2000). Proteins move along the 
gradient until they reach the pH of their isoelectric point, a point at which the net 
charge of a protein is zero. This is called isoelectric focusing. Proteins are then 
ftirther separated in the second dimension, SDS-PAGE, according to their molecular 
weights (MWs), A distinct distribution of protein spots can be obtained for each kind 
of biological sample and this protein "map" can act as a biological fingerprint. With 
different gel sizes and pH gradients, an average of 1000-2500 protein spots can be 
resolved simultaneously. The number can even be expanded to over 10000 in some 
conditions after optimization (Carrette et al., 2006). 
2-DE has undergone many different modifications since its invention, including the 
use of pH gradient instead of ampholyte-based gradient in 1970's (Gorg et al., 2000), 
optimization of protein extraction and solubilizations from different biological 
samples (Rabilloud et al., 1997; Wang et al., 2008), the development of narrow-
overlapping IPG strips for sample prefractionation and higher resolution (Bjellqvist 
et al., 1993) and improvements in protein detection methods like the use of 
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fluorescent dyes such as Sypro Ruby and the introduction of two-dimensional 
fluorescence difference gel analysis technology (2D-DIGE) (Marouga et al., 2005). 
Despite the great advancement, there are still many drawbacks and limitations in 2-
DE. Not all proteins extracted can be completely resolved in a 2D gel. Large or 
hydrophobic proteins are difficult to solubilize and thus do not enter the IPG strip 
well. Proteins with isoelectric point below 3 (too acidic) or above 10 (too basic) are 
not well separated (Gorg et al., 2000). Low-copy proteins are usually under-
represented in 2D gels. In a study of yeast mRNA and protein expression, no low-
abundance proteins like regulatory proteins were visible in 2D gels while highly 
abundant proteins with relatively long half-life were overwhelmingly represented 
(Gygi etal.，1999). 
1.4.3 GeI-free proteomics 
To enhance coverage of hydrophobic or large proteins, gel-free proteomics 
separating protein mixtures by liquid chromatography had been developed. Proteins 
were first prefactionated and digested into peptides by enzymes like trypsin. Peptides 
were then further separated by liquid chromatography based on two or more 
parameters. Yates and coworkers performed strong cation exchange chromatography 
prior to reverse phase chromatography, separating peptides based on two different 
parameters, net charge and hydrophobicity (Link et al., 1999). This technique was 
called multidimensional protein identification technology (MudPIT). To reduce 
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under-sampling of peptides, consequence of sample complexity and the resulting 
random sampling for MS/MS, targeted approaches like isotope-coded affmity tag 
(ICAT) (targeting cysteine peptides) (Gygi et al., 1999) and combined fractional 
diagonal chromatography (COFRADIC) (targeting cysteine, methionine or N-
terminal peptides) (Gevaert et al., 2002; Gevaert et al., 2003) were successively 
developed. These techniques allow peptide quantitation as well as study of 
posttranslational modifications (Gevaert et al., 2006). 
1.4.4 Mass spectrometry 
Mass spectrometry (MS) is a powerful tool for protein identification. The separated 
protein spots from 2-DE usually undergo enzymatic digestion with trypsin into 
peptides, masses of which can be measured by mass spectrometry. Protein can be 
identified by its own set ofunique peptide masses, called peptide mass fingerprinting 
(PMF) (Kussmann et al., 2005). 
There are three types of MS commonly used for protein identification, namely 
matrix-assisted laser desorption / ionization (MALDI), Surface-Enhanced Laser 
Desorption/Ionization (SELDI) and electrospray ionization (ESI) mass spectrometry 
(MS). In MALDI-MS, a matrix, an organic acid with fairly low molecular weight 
and strong optical absorption in UV, has to be applied. It co-crystallizes with the 
digested protein sample and helps the ionization of peptide. When a laser is pulsed 
onto the crystalline surface, and concomitantly desorbs and ionizes the peptide into 
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singly-charged peptide ions (Duncan et al., 2008). SELDI-MS is a variation of 
MALDI-MS. In SELDI-MS, biological samples are spotted on surface with specific 
affmity, which acts as a solid-phase extractor under chemical andA)r biochemical 
modifications. The selective retention of proteins makes SELDI-MS advantageous in 
biomarker discovery and clinical proteomics (Tang et al., 2004). In ESI-MS, 
electrospray disperses liquid sample into fine aerosol. Peptides are multiply 
protonated and then dispersed from solution to gas phase yielding multiple charged 
ions (Kussmann et al., 2005). After ionization, determination of peptide mass is by 
measuring the time for peptide ions flying to the detector (time-of-flight detector, 
ToF). 
By comparing the PMF of a protein sample with the theoretical PMFs in database, 
known proteins can be identified. However, for novel protein samples without a 
sequence record in database, MS/MS approach can be adopted to read out the partial 
amino acid sequence by selectively fragmentizing the peptides isolated in MS 
(Kussmann et al., 2005). 
1.4.5 Proteomics as tool for diabetes research 
With the advancement of proteomic technology, increasing number of researches 
focusing on protein profiling of diabetes-related organs/tissues have been performed, 
including but not limited to insulin target tissues: adipose tissue, liver and skeletal 
muscles, plasma or sera of diabetic subjects/models and even saliva. 
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As insulin target tissues, adipose tissue, muscle cells and hepatocytes are all by 
different means involved in T2DM and insulin resistance. In order to detect the effect 
and markers of high fat diet and insulin resistance, Schmid et al. performed a 2-DE 
study (Schmid et al., 2004). Muscle, white and brown adipose tissues and liver were 
taken from normal mice fed with a high fat or a normal chow diet. Many 
differentially expressed proteins between obese and lean mice were detected, out of 
which more than half were found in brown adipose tissue. Several of these proteins 
were stress and redox proteins. In addition, enzymes involved in glycolysis and 
respiratory chain, such as a-enolase and ubiquinol-cytochrome C reductase complex 
core protein 1，were down-regulated in high fat fed animals. This hinted at a 
competition between fatty acid and glucose as an oxidative fuel source under high fat 
diet. The authors concluded that high fat fed animals increase their energy 
expenditure to defend against weight gain by regulating the brown adipose tissue 
proteome, which in tum leads to energy dissipation. 
To unravel the molecular basis of the relationship between mitochondrial 
dysfunction, lipolytic responsiveness, and insulin resistance in adipocytes, Cho et al. 
lipolytically stimulated mouse adipocyte cell line, 3T3-L1, with isoproterenol or 
TNF- a and isolated the mitochondrial fractions for 2-DE and Westem blot study 
(Cho et al., 2009). Isoproterenol treatment up-regulated several proteins involved in 
fatty acid oxidation, TCA cycle and oxidative phosphorylation while the up-
28 
regulating effect of TNF-a on those proteins was less significant. However, both 
isoproterenol and TNF-a treatment significantly down-regulated proteins involved in 
oxidative stress dissipation, suggesting that both isoproterenol and TNF- a-treated 
mitochondria experience similar type of oxidative damage from lipolytic stimulation. 
But isoproterenol-treated mitochondria may overcome this damage through the high 
expression of prohibitin, which was not detected in TNF-a-treated mitochondria. 
Analysis of liver protein expression profiles connected to hepatic insulin resistance 
was performed using an insulin resistant hamster model (Morand et al., 2005). In 
their search for mechanisms linking development of hepatic insulin resistance and 
overproduction of atherogenic lipoproteins the authors analysed the proteome of the 
liver ER. By 2-DE, 34 differentially expressed proteins were identified. Hepatic ER 
proteins ER60, ERp46, ERp29, glutamate dehydrogenase and TAP1 were all 
decreased, while alpha-glucosidase, P-glycoprotein, fibrinogen, protein disulfide 
isomerase, GRP94 and apolipoprotein E were all increased in the insulin resistant 
animal. 
To characterize the metabolic features of mice fed with high-fat diet (HFD) and 
investigate the impact of leptin upon lipogenesis, Jiang et al. performed 2-DE and 
compared the protein profiles of white adipose tissues (WAT) of mice fed with 
standard chow and their littermates fed with HFD (Jiang et al., 2009). 
Hyperleptinemia was observed at an early stage during the progressive accumulation 
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of fat mass in HFD-fed mice. In WAT, HFD down-regulated several proteins 
involved in lipid, fatty acid and carbohydrate metabolism and up-regulated several 
stress response- or detoxification-related proteins like heat shock cognate 71 kDa 
protein. Lipogenesis-related enzymes, including ATP-citrate lyase, fatty acid 
synthase, transketolase and malic enzyme 1，displayed prominent suppression in 
response to HFD. Westem blot results also showed reduced expression of ATP-
citrate lyase and fatty acid synthase in liver of HFD-fed mice. However, this 
suppression ofhepatic proteins expression was not observed in HFD-fed db/db mice, 
which suffer from leptin receptor deficiency and are thus leptin-resistant. The authors 
suggested the involvement of leptin in adaptive responses to ovemutrition by 
suppressing lipogenesis. 
Skeletal muscle plays a role in glucose homeostasis by taking up and utilising 
glucose in an insulin dependent manner. Hittel et al. characterized cytosolic skeletal 
muscle proteins in lean and obese individuals. They identified increased levels of 
adenylate kinase, glyceraldehyde-3-phosphate dehydrogenase and aldolase A in 
skeletal muscles of obese women compared with lean women (Hittel et al., 2005). 
Hojlund et al. have recently characterised the human skeletal muscle proteome from 
healthy subjects by combining lDGE and HPLC electrospray ionisation tandem 
mass spectrometry (Hojlund et al., 2008). Nearly a thousand different proteins were 
identified. Beside muscle contractile proteins, many identified proteins were 
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involved in glucose and lipid metabolism. Mitochondrial proteins accounted for a 
fairly large percentage (22%) of all proteins identified. Enzymes involved in cell 
signaling and calcium homeostasis pathways were also found. 
Since all tissues are in contact with blood, proteins secreted or leaking from the 
different tissues are reflected in the circulation. Blood sample is relatively easy and 
safe to collect, making a good source to look for biomarkers for diagnosis or 
screening. Haptoglobin level was found to be elevated in serum of T2DM patients 
when compared to control serum. Several proteins involved in the inflammatory 
response, like a -2 macroglobulin, fibrinogen, complement C3 and C1 inhibitor, were 
also altered in serum of patients with insulin resistance (Zhang et al., 2004). 
Increased serum level of Apolipoprotein CIII was found in T2DM patients in a 
recently study (Sundsten et al., 2008) and is also considered as a cardiovascular risk 
factor (Gervaise et al., 2000). 
To identify salivary biomarkers for T2DM, Rao et al. separated salivary proteins 
with strong cation-exchange chromatography followed by LC-MS/MS (Rao et al., 
2009). Quantitation was based on spectral counting, i.e., the total number of tandem 
mass spectra matched to the protein. Out of 487 proteins identified, a majority of the 
differently abundant proteins are predicted to have functions in metabolism, followed 
by the functional categories of development, cell organization and biogenesis, 
immune ftinction, etc. Inflammatory factors like protease inhibitors CysC, leukocyte 
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elastase inhibitor, and uteroglobin were increased in saliva of T2DM patients than 
that of healthy subjects and it is consistent with the chronic inflammatory state in 
progression of diabetes and metabolic syndrome. A2MG was also elevated in 
diabetic saliva and Westem blot analysis showed progressive elevation of A2MG 
level in different diabetic stages: with impaired glucose tolerance, with both impaired 
glucose tolerance and impaired fasting glucose and diagnosed diabetes. It was 
suggested that A2MG variation could be adopted as a candidate biomarker in 
prediabetic saliva for screening of preclinical diabetes. 
1.5 Objective and significance 
Current hypoglycemic agents for treating diabetes have various side effects including 
like nausea and vomiting for metformin, hypoglycemia for sulphonylureas and 
unwanted weight gain and even potential heart or liver failure for thiazolidinedione. 
Berberine, with promising hypoglycemic and weight-lowering effect, appears to 
have fewer side effects (only mild constipation was reported in clinical cases (Yin et 
al., 2008c)). This project aimed at understanding the underlying mechanisms of the 
anti-diabetic effect of berberine in the hope of revealing good therapeutic targets for 
treating diabetes. In this project, the effect of berberine on visceral adipose tissue of 
diabetic db/db mice and 3T3-L1 adipocytes was investigated in proteomic approach. 
Among various target sites of action ofberberine, adipose tissue deserves an in-depth 
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investigation as fat mass reduction was accounted for the weight-lowering effect of 
berberine. The role of adipose tissue as an endocrine organ and its causal role in the 
pathophysiology of diabetes are widely recognized with substantial evidences 
(reviewed above). Metabolic alterations in both in vivo and in vitro models were 
investigated, followed by proteomic study of the visceral adipose tissues (in vivo) or 
3T3-L1 adipocytes (in vitro) and Westem blotting, in an attempt to studying the 
changes in the metabolic pathways and other proteins after berberine treatment. 
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2. Materials and Methods 
2.1 Drug preparation 
Berberine hydrochloride (BBR) tablets 100mg (Wah Kin Pharmaceutical Products) 
were ground and dissolved in warm Milli-Q water (Millipore) to a final 
concentration 2mg/mL. The solution was filtered through a filter of 0.22p.m porosity 
and stored at -20°C for up to 1 week. The BBR solution prepared was for both 
animal and cell culture experiment. 
2.2 Animal experiment 
12-week-old obese db/db mice and lean m+/db mice were obtained from the 
Laboratory Animal Services Centre of The Chinese University of Hong Kong. The 
animals were maintained on 12h/12h dark/light cycle and received standard chow 
(Labdiet) and tap water ad libitum during the study unless otherwise specified. 
For estimating a safe dose of BBR for db/db mice, a preliminary treatment with 
different doses of BBR by gastric feeding was performed. Preliminary results 
showed that high dose ofBBR (lOOmg/kg body weight or above) killed the mice in 2 
weeks (data not shown). Yellow BBR powder was found in the gut of dead mice and 
probably blocked the alimentary canal and killed the mice. Mice treated with 
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50mg/kg bodyweight BBR appeared healthy and normal with observable weight loss 
and thus, 50mg/kg body weight was chosen as the optimal dose for the treatment in 
further experiment. For BBR treatment, 20 obese db/db mice were divided into 2 
groups, BBR-treated group and control group. Each mouse in the BBR-treated group 
was administered with 50mg/kg body weight BBR daily by gastric feeding. Water 
was fed to the mice in the control group instead. The treatment lasted for 7 weeks. 
Body weight was measured weekly. In the moming of the last day of treatment 
period, BBR was administered by gastric feeding as usual. Thirty minutes later 
(t=Omin), fasting blood glucose level of the mice was measured, immediately 
followed by intraperitoneal injection of D-glucose solution (lg/kg body weight). 
Blood sample was collected from tail and glucose level was monitored with Bayer 
Elite Glucometer (Bayer Healthcare). Blood glucose levels were measured at 
t=45min, t=90min and t=120min respectively. For comparison of protein profiles of 
the visceral adipose tissues, all the mice were sacrificed by cervical dislocation the 
next day to collect their visceral white adipose tissues. As the mice were fasted 
ovemight before glucose tolerance test, the mice were allowed access to food one 
more day so that the visceral adipose tissues collected would be at normal but not 
fasted state. The tissue samples were ground in liquid nitrogen and stored at -80°C 
until use. For the comparison of proteome of the visceral adipose tissue of obese 
db/db mice and that of lean m+/db mice, tissues samples from 5 mice of each group 
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were collected and pooled together. For the comparison of the visceral adipose tissue 
of BBR-treated and untreated db/db mice, tissue samples from 8 mice of each group 
were collected and pooled together. 
2.3 Comparison of proteome of visceral white adipose tissue: 
obese db/db mice vs lean m+/db mice and BBR-treated vs control 
db/db mice 
2.3.1 Protein sample preparation from adipose tissue 
Ice-cool n-hexane (Labscan) was added to the ground adipose tissues. The samples 
were sonicated for 15min with ultrasonic cleaner (Model 5210，Branson) and 
centrifuged at 13,000g for lOmin (Tabletop High-speed Microcentrifuge, Hitachi 
Koki). The supematants and fat pads at the top were discarded. Ice-cool 20% 
trichloroacetic acid (TCA)/acetone was added to resuspend the tissue pellets and the 
samples were incubated ovemight at -20°C for protein precipitation. After 
incubation, the samples were centrifuged at 15,000g for lOmin at 4°C (Tabletop 
High-speed Microcentrifuge, Hitachi Koki). The protein pellets were washed thrice 
with ice-cool acetone and briefly dried with SpeedVac (LABCONCO). The protein 
pellets were resolubilized in rehydration buffer containing 8M urea (PlusOne, GE 
Healthcare), 2M thiourea, 2% (w/v) CHAPS and 0.002% (w/v) bromophenol blue. 
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The samples were centrifuged at 15,000rpm for lOmin Tabletop High-speed 
Microcentrifuge, Hitachi Koki) and the supematants were transferred to another 
1.5mL microcentrifuge tube for storage at -80°C before use. 
2.3.2 Protein quantitation 
Protein concentration of each sample was assayed using PlusOne 2-D Quant Kit (GE 
Healthcare) according to the manufacturer's instructions. A standard curve was 
prepared for every quantitation using the 2mg/mL bovine serum albumin (BSA) 
standard solution provided. The assay range is 0.5-50^ig. The standard curve was 
plotted using protein amount against absorbance at 480nm and the amount of the 
unknown protein samples can be found out from the standard curve with their 
absorbance accordingly. 
2.3.3 2D Gel electrophoresis 
Isoelectric focusing (IEF) was performed using Ettan IPGphor III isoelectric 
focusing system (GE Healthcare). The samples were quantified by PlusOne 2-D 
Quant Kit as mentioned and normalized to lOOp,g. Rehydration buffer and 2% (v/v) 
Pharmalyte (GE Healthcare) of corresponding pH range were added to bring up to a 
total volume of 125uL. The prepared sample was applied to the Immobiline DryStrip 
(7cm，linear pH3-10) by rehydration loading ovemight. The first dimension (IEF) 
was performed at 13500Vhr. 
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Before the second dimension, the IPG strip was equilibrated at room temperature for 
15min in the SDS equilibration buffer containing 50mM Tris-HCl pH8.8, 6M urea 
(USB), 30% (v/v) glycerol, 2% (w/v) SDS and 0.002% (w/v) bromophenol blue. 1% 
(w/v) DTT was added prior to use. The strip was then briefly washed with Milli-Q 
water (Millipore) and further equilibrated at room temperature for another 15 
minutes in the SDS equilibration buffer containing 50mM Tris-HCl pH8.8, 6M urea, 
30% (v/v) glycerol, 2% (w/v) SDS, 0.002% (w/v) bromophenol blue and 2.5% (w/v) 
iodoacetamide. 
The strip was washed with Milli-Q water (Millipore) briefly again and put onto the 
4% stacking gels and 12% separating gels with 1mm gel thickness. The strip was 
covered with 400pL agarose sealing solution with 0.5% (w/v) agarose in SDS 
electrophoresis buffer containing 25mM Tris-base, 192mM glycine, 0.1% (w/v) 
SDS. The agarose sealing solution was allowed to polymerize at room temperature. 
The gels were then run at 80V for 30 with the SDS electrophoresis buffer mentioned 
above using the electrophoresis system (XCell Surelock mini-vertical electrophoresis 
system, Invitrogen Life Technologies). 
After the second dimension run, the gels were washed with Milli-Q water and then 
stained with 50mL Coomassie staining solution which contains 45% (v/v) methanol, 
10% (v/v) acetic acid, 0.15% (w/v) Coomassie Brilliant Blue R-250 (Sigma) for 1-
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2h. The gels were destained in destaining solution containing 45% (v/v) methanol, 
10% (v/v) acetic acid in Milli-Q water. 
2.3.4 Image analysis 
The gels were scanned under visible light at 300dpi using ImageScanner (Amersham 
Biosciences). Analysis was performed using the computer program, ImageMaster 2D 
Platinum 5.0 (Amersham Biosciences). Spots were detected automatically with the 
following parameters: smooth 2, minimum area 6 and saliency 1.5. Manual spot 
editing was performed if necessary. The same distinct, well-focused spot was marked 
as "landmark" in all gels. Auto-matching and pair-up was performed using the 
software, followed by necessary manual editing (addition or deletion ofpairs). Spot 
pairs with over 1.5-fold change in %vol and all-or-none spots without pair on the 
other gel were identified. 
2.3.5 In-gel digestion and protein identification by MALDI-ToF MS 
Spot pairs with over 1.5-fold change in %vol and all-or-none spots without pair were 
excised after image analysis. The spots were first destained with spot-destaining 
solution containing 50mM ammonium bicarbonate and 50% (v/v) methanol and then 
dehydrated with acetonitrile (ACN). The ACN liquid was then removed and the 
spots were completely dried with SpeedVac (LABCONCO). 5p,L of 50mM 
ammonium bicarbonate containing 20ng/|aL Sequencing Grade modified trypsin 
(Promega) was added to each spot for rehydration and protein digestion. The samples 
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were incubated overnight at 37°C. 4|iL extraction buffer (75% v/v ACN and 2.5% 
v/v TFA) was added to the spots, which were then sonicated for lOmin with 
ultrasonic cleaner (Model 5210, Branson). 0.4^iL digested protein sample was then 
spotted onto the mass spectrometry plate (Applied Biosystems) twice or thrice, 
depending on the size of the gel spot, and then 0.4^iL matrix (x-cyano-4-
hydroxycinnamic acid) was spotted once onto the air-dried plate. Mass spectrometry 
was performed with the 4700 proteomics analyzer (Applied Biosystems). Mass 
tolerance of 0.5 atomic mass unit and peptide mass tolerance of 50ppm was set in all 
searches Oxidation of methionines was taken into account for the modification. The 
peptide mass fingerprint data collected were then searched against the NCBI 
database with the Mus taxonomy selection. The proteins with C.I.% larger than 99 
were regarded as confirmed match. 
2.4 Cell culture experiment 
Stock of mouse pre-adipocytes, 3T3-L1, was a kind gift from Professor Cheung 
Wing Tai in The Department of Biochemistry of The Chinese University of Hong 
Kong. The cell line was grown in high-glucose DMEM (Invitrogen Life 
Technologies) supplemented with 4.93% (v/v) sodium bicarbonate (Invitrogen Life 
Technologies), 10% (v/v) FBS (Hyclone) and penicillin (lOOU/mL) (Invitrogen Life 
Technologies). The cell line was kept in an incubator of 5% CO2 at 2>TC in 
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humidified atmosphere. For adipocyte differentiation and BBR treatment, 3T3-L1 
cells were seeded into 35mm x 10mm tissue culture dishes (Nunclon) or 24-well 
tissue culture plates (Nunclon). Two days post-confluence (Day 0)，cells were grown 
in differentiation medium with 0.5mM isobutylmethylxanthine (Sigma), lp.M 
dexamethasone (Sigma) and lOp,g/mL insulin (Sigma) dissolved in "standard" 
DMEM medium for 2 days. Then the cells were changed to insulin medium with 
lO^g/mL insulin (Sigma) dissolved in "standard" DMEM medium for 2 more days. 
After that, the cells were grown and re-fed with the "standard" DMEM medium 
every 2 days. On day 10，>90% of the cells exhibited adipocyte phenotype and were 
regarded as mature. 
In an attempt to investigate whether the in vivo weight-lowering effect of BBR was 
due to the loss of triglyceride accumulated in mature adipocytes or the inhibition of 
differentiation in pre-mature adipocytes, both prolonged treatment on mature 
adipocytes and short-term treatment on pre-mature adipocytes were performed. The 
former aimed at mimicking the in vivo situation of visceral adipose tissues exposed 
to long term daily BBR treatment in human, while the latter revealed the inhibitory 
effect of BBR on differentiation and lipid accumulation of pre-mature adipocytes, as 
reported in previous studies (Huang et al., 2006; Hu et al., 2009). For prolonged 
experiments of mature adipocytes, berberine treatment began on day 10 for 72h. For 
short-term experiments of pre-mature adipocytes, berberine treatment was performed 
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on day 4 for 24h. 5uM BBR solution was added to DMEM medium for treating both 
mature and pre-mature adipocytes. 
2.5 Oil Red 0 staining 
Oil Red 0，with sharp red color and readily binds to lipid, can be used to stain and 
measure intracellular triglyceride content (Choi et al., 2006). The cells were washed 
with PBS twice and fixed with 10% formalin at room temperature for lh. 60% 
isopropanol (v/v) in Milli-Q water was used to wash the fixed cells, which were then 
completely air-dried. The cells were then stained with filtered Oil Red 0 staining 
solution containing 0.18% (w/v) Oil Red 0 (Sigma) and 60% (v/v) isopropanol in 
Milli-Q water at room temperature with gentle shaking for lOmin. The staining 
solution was then removed and the cells were washed in running distilled water for at 
least 4 times. The red dye retained in the cells was eluted into 100% isopropanol and 
the absorbance at 540nm of the eluted dye was measured as a semi-quantitative assay 
of intracellular triglyceride level, 
2.6 Glycerol determination 
To estimate the rate of lipolysis of the cells after BBR treatment, glycerol content of 
the culture medium was determined. Higher glycerol content in the culture medium 
indicates a higher rate of lipolysis of cells. Media ofBBR-treated and control 3T3-L1 
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cells were collected after treatment. The Free Glycerol Reagent (Sigma) with 
Glycerol Standard solution from the same company (Sigma) as standard was used 
according to manufacturer's instructions. 
2.7 In vitro comparison of proteomes of BBR-treated and control 
3T3-L1 adipocytes 
2.7.1 Protein sample preparation from 3T3-L1 cells 
The cells were washed thrice with PBS and scraped out with a cell scraper (Coming). 
Ice-cool 20% TCA/acetone was added to the cells and the samples were ultra-
sonicated on ice for 10s before ovemight incubation at -20°C for protein 
precipitation. The samples centrifuged at 15000g for lOmin at 4°C (Tabletop High-
speed Microcentrifuge, Hitachi Koki). The protein pellets were washed thrice with 
ice-cool acetone and briefly dried with SpeedVac (LABCONCO). The protein pellets 
were resolubilized in rehydration buffer containing 8M urea (PlusOne，GE 
Healthcare), 2M thiourea, 2% (w/v) CHAPS and 0.002% (w/v) bromophenol blue. 
The samples were centrifuged at 15,000g for lOmin (Tabletop High-speed 
Microcentrifuge, Hitachi Koki) and the supematants were transferred to new 1.5mL 
microcentrifuge tubes for storage at -80°C before use. 
2.7.2 Protein quantitation 
Same as section 2.3.2. 
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2.7.3 2D Gel electrophoresis 
Same as section 2.3.3. 
2.7.4 Image analysis 
Same as section 2.3.4. 
2.7.5 In-gel digestion and MALDI-ToF MS 
Same as section 2.3.5. 
2.8 Western Immunoblotting 
2.8.1 Protein sample preparation of BBR-treated and control 3T3-L1 
Same as section 2.7.1. 
2.8.2 SDS-PAGE 
A 10-well polyacrylamide gel containing 4% stacking gels and 12% separating gels 
with 1mm gel thickness was set. 40p_g of the protein samples were mixed with 
loading dye and heated at 99°C for 5min before being loaded into each well. 4^L of 
biotinylated protein ladder (Cell signaling technology) was used for each gel. The 
gels were run in a electrophoresis system (XCell Surelock mini-vertical 
electrophoresis system, Invitrogen Life Technologies) and run with 80V for 30min 
and then 180V for lh using the SDS electrophoresis buffer mentioned in section 
2.3.3. 
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2.8.3 Protein blotting 
After running, the gel was washed with Milli-Q water, and placed inside the iBlot™ 
Dry Blotting System (Invitrogen Life Technologies) together with the provided iBlot 
Anode Stack (containing the PVDF membrane, 0.2|xm, low fluorescence), filter 
paper soaked in Milli-Q water and the iBlot^^ Cathode Stack. Any trapped air 
bubble that may interfere with efficient protein transfer was carefully removed using 
the debubbling Roller. Default protocol P3 was used for 7 minutes in order to 
perform the blotting. 
2.8.4 Membrane blocking and antibody incubations 
The membrane was incubated in 25mL blocking buffer (TBST containing 2mM Tri-
HC1, 15mM NaCl, pH7.5, 0.1% v/v Tween-20 with 5% w/v bovine serum albumin) 
for lh at room temperature with gentle shaking. Then, the membrane was washed for 
5 minutes with 15mL TBST (2mM Tri-HCl, 15mM NaCl, pH7.5, 0.1% Tween-20) 
for three times. The membrane was then incubated with primary antibody (1:1000 
dilution) (Cell signaling technology) in 5mL TBST with gentle agitation ovemight at 
4°C. After that, the membrane was washed three times for 5 minutes with 15mL 
TBST. HRP-conjugated secondary antibody (1:2000 dilution) (Cell Signaling 
Technology) and HRP-conjugated anti-biotin antibody (1:1000 dilution) (Cell 
Signaling Technology) in 5mL TBST was then added to detect biotinylated protein 
markers and the primary antibody. Gentle agitation for 1 hour was allowed at room 
45 
temperature. The membrane was washed again for three times for 5 minutes with 
15mL TBST. 
2.8.5 Detection of Proteins 
The membrane was shaked in 4mL LumiGLO® (200^iL 20X LumiGLO® and 200^iL 
20X peroxide in 3600^iL Milli-Q water) (Cell Signaling Technology) at room 
temperature for 2min. The membrane was then wrapped in plastic wrap. 
Chemiluminescence image detection was performed for 3min using Lumi-Imager F1 
(Roche). Detection of band intensity was performed using the computer program, 
ImageMaster 2D Platinum 5.0 (Amersham Biosciences). 
2.9 Statistical analysis 
Data were presented as mean+SD. Wherever p-value was provided, paired t-tests 




3.1 Comparison of total protein profiles of visceral adipose tissue 
of obese db/db and lean m+/db mice 
Visceral adipose tissues were collected from 5 obese db/db mice and 5 lean m+/db 
mice, respectively and pooled together for protein extraction. Four replicates of2-DE 
gel were run and proteins showing differential abundance of over 1.5 fold in all 4 
sets of gel were picked for mass spectrometry analysis. 2D gel pattems were shown 
in Fig. 3.1a and 3.1b and proteins of differential abundance were listed in Table 3.1. 
Several proteins involved in glycolysis were up-regulated in adipose tissue of obese 
db/db mice compared with that of lean m+/db mice while proteins involved in TCA 
cycle and oxidative phosphorylation were down-regulated. Proteins involved in 
lipolysis, including lipase, hormone sensitive isoform 2 and carboxylesterase 3，were 
both down-regulated. Down-regulation of stress-related proteins, superoxide 
dismutase 1 and carbonic anhydrase 3，may indicate oxidative stress in adipose 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.2 Effect of berberine on glucose metabolism of obese db/db mice 
After 49-day treatment of berberine (BBR) (gastric feeding 50mg/kg body weight 
per day), body weight, fasting blood glucose level of the db/db mice were measured 
and glucose tolerance test was performed. 
Body weight of the BBR-treated db/db mice was reduced by 25.33+2.93% whereas 
body weight of water-treated control decreased by 14.00+3.75% only (p<0.05). 
Figure 3.2.1 shows the change in body weight ofboth BBR-treated and control mice 
throughout the whole treatment period. 
Percentage change in weight of db/db mice after 
berberine treatment 
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Fig. 3.2.1 Bodv weight of BBR-treated mice dropped more drastically than that 
of coDtrol db/db mice, n=8 in both BBR-treated and control groups, *p<0.05. 
At the end ofthe treatment period, the average fasting blood glucose level ofcontrol 
db/db mice was 466.83+38.34mg/dL and that of BBR-treated mice was 
266.80+36.0mg/dL. The difference was statistically significant with p==0.000151. 
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Fig. 3.2.2 Berberine treatment resulted in a lower fasting blood glucose level in 
db/db mice. 
Glucose tolerance test indicates how quickly the body can clear glucose intake to the 
blood. 120 minutes after intraperitoneal glucose injection, the average blood glucose 
level of the control db/db mice was 567.43+31.53mg/'dL and that of BBR-treated 
mice was 466.60±53.36mg/dL. Though the difference was not large, it is still 
statistically significant with p-value=0.0028. Figure 3.2.3 shows the change ofblood 
glucose of the mice after glucose injection. 
Effect of berberine treatment on glucose-
lowering ability of db/db mice 
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Fig. 3.2.3 Mild improvement in glucose-lowering effect was resulted after 
berberine treatment. 
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3.3 Comparison of the protein profiles of visceral adipose tissue of 
BBR-treated and control db/db mice 
After 7 weeks of berberine treatment, the mice were sacrificed (8 mice from BBR-
treated group and 8 mice from control group) and visceral adipose tissues were 
collected and pooled together for 2-DE. Four replicates were run and protein spots 
with differential abundance over 1.5 fold in all 4 sets of replicates were picked for 
mass spectrometry analysis. 2D gel pattems were shown in Fig. 3.3a and 3.3b and 
proteins of differential abundance were listed in Table 3.3. 
Several enzymes involved in glycolysis were up-regulated. Proteins responsible for 
beta-oxidation and lipolysis also increased after berberine treatment. Three stress-
related protein increased as well, including carbonic anhydrase 3，calreticulin and 
annexin A1. The increase of mitogen activated protein kinase 1 (MAPK1), the 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.4 Effect of berberine treatment on 3T3-L1 adipocytes 
Mature 3T3-L1 adipocytes (day 10) grown in 24-well plates were treated with 
various concentrations of berberine in medium for 72h (prolonged treatment) in 
order to study the effect of berberine on lipid metabolism of adipocytes. A 72h 
treatment was performed as previous report showed that prolonged treatment with 
berberine could significantly reduce the size of lipid droplets (Lee et al., 2006). To 
study the effect of short-term berberine treatment on lipid-accumulating pre-mature 
adipocytes, 3T3-L1 adipocytes (day 4) grown in 24-well plates were treated with 
5 i^M berberine for 24h. Oil Red 0 staining was performed to estimate effect of 
berberine treatment on the intracellular accumulation and glycerol concentration in 
the media was determined after treatment so as to estimate the rate of lipolysis. 
3.4.1 Berberine treatment inhibited intracellular triglyceride accumulation in 
both mature and pre-mature 3T3-L1 adipocytes 
For the prolonged (72h) BBR treatment in mature 3T3-L1 adipocytes, the average 
absorbance of untreated 3T3-L1 cells at 540nm was 1.10+0.065 and that of cells 
treated with l^iM, 5^iM and 15|iM berberine (n=8 in all 4 groups) was 0.93+0.044, 
0.75+0.046 and 0.76+0.034 (p<0.05) respectively as shown in Figure 3.4.1.1 and 
3.4.1.3. Prolonged BBR treatment at l^iM, 5^iM and 15|iM could reduce intracellular 
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accumulation of triglyceride in mature adipocytes by 15.3%, 31.9% and 31.6% 
respectively. 
For short-term BBR (24h) treatment in lipid-accumulating pre-mature 3T3-L1 
adipocytes, the average absorbance of untreated 3T3-L1 cells at 540nm was 
0.15+0.0125 and that of cells treated with 5 i^M berberine was 0.13+0.0048 (n=4 in 
both groups, p<0.05) as shown in Figure 3.4.1.2. Short-term BBR treatment at 5 i^M 
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Fig, 3.4.1.1 Berberine inhibited intracellular lipid accumulation in mature 3T3-L1 
adipocytes. The absorbance of Oil Red 0 stain at 540nm was lower in mature 
adipocytes treated with berberine for 72h in a dose-dependent manner in a lower 
dose (<5|iM). The inhibitory effect was similar in higher dose (5^iM and 15^M). 
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Fig. 3.4.1.2_Berberine inhibited intracellular lipid accumulation in pre-mature 
3T3-L1 adipocytes. The absorbance of Oil Red 0 stain at 540nm was lower in pre-

























































3.4.2 Berberine treatment enhanced lipolysis in mature 3T3-L1 adipocytes but 
inhibited lipolysis in pre-mature 3T3-L1 adipocytes 
For the prolonged (72h) BBR treatment in mature 3T3-L1 adipocytes, the average 
glycerol concentration of culture media from untreated 3T3-L1 adipocytes was 
0.042+0.0057 mg/mL and that of cells treated with l^iM, 5 i^M and 15^iM berberine 
(n=3 in all 4 groups) was 0.059+0.0024 mg/mL, 0.056+0.0054 mg/mL and 
0.058+0.0024 mg/mL, respectively (p<0.05) as shown in Figure 3.4.2.1. 
For short-term BBR (24h) treatment in lipid-accumulating pre-mature 3T3-L1 
adipocytes, the average glycerol concentration of culture media from untreated 3T3-
L1 cells was 0.015+0.0009 mg/mL and that of cells treated with 5|iM berberine was 
0.010+0.0007 mg/mL (n=3 in both groups, p-value=0.0015<0.05) as shown in Figure 
3.4.2.2. 
3.4.3 Color change in culture media after berberine treatment 
It was observed that culture media of 3T3-L1 adipocytes treated with berberine 
tumed orange or even yellow after 3-day treatment. It may indicate an increase in 
energy metabolism or change to anaerobic respiration. 
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Fig. 3.4.2.1 Glvcerol concentration of culture media from mature 3T3-L1 
adipocytes increased after berberine treatment for 72h. indicating an increase in the 
rate oflipolysis. 
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Fig. 3.4.2.2__Glvcerol concentration of culture media from pre-mature 3T3-L1 
adipocytes decreased after treated with 5uM berberine for 24h. indicating a decrease 
in the rate oflipolysis. 
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3.4.4. Comparison of protein profiles between berberine-treated and control 
3T3-L1 adipocytes 
As treatment with 5 i^M and 15^M berberine gave similar results in Oil Red 0 
Staining and glycerol determination, treatment with 5^iM berberine for 72h was 
chosen for 2-DE protein profile comparison. Four replicates were run and protein 
spots with differential abundance over 1.5 fold in all 4 sets of replicates were picked 
for mass spectrometry analysis. 2D gel patterns were shown in Fig. 3.4a and 3.4b and 
proteins of differential abundance were listed in Table 3.4. 
Proteins involved in carbohydrate and lipid metabolism were altered. Carnitine 0 -
palmitoyltransferase 2，which is responsible for the transport of fatty acid into 
mitochondria for beta-oxidation, was up-regulated. Triacylglycerol hydrolase, which 
is involved in lipolysis, also increased after berberine treatment. It is also noteworthy 
that several stress-related proteins were up-regulated by berberine, including heat 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.4.5 Western blotting 
Total proteins were extracted from BBR-treated (72h) or control mature 3T3-L1 
adipocytes. All westem blotting experiments were performed three times. 
To confirm activation of AMPK by BBR, AMPK-alpha and phospho-AMPK-alpha 
(Thrl72) were detected. After normalization with the intensity of AMPK-alpha, level 
of phospho-AMPK-alpha (Thrl72) of BBR-treated 3T3-L1 was 2.34-fold of that of 
control 3T3-L1 cells as shown in Fig. 3.4.5.1. 
BBR- Ctrl 
treated 
AMPK-alpha S t t t k ^ 0 W l k 
Phospho-AMPK- g ^ ^ ^ . 
alpha ^ ^ ^ " ^ 
Fig. 3.4.5.1 Berberine treatment enhanced the activation of AMPK-abha in 
mature 3T3-L1 adipocytes. 
To investigate whether inhibition oflipid accumulation in mature 3T3-L1 adipocytes 
by berberine is associated with the JNK pathway, SAPK/JNK and phospho-
SAPK/JNK (Thrl83/Tyrl85) were also detected. After normalization with the 
intensity of JNK/SAPK, level of phospho-SAPK/JNK (Thrl83/Tyrl85) of BBR-
treated 3T3-L1 was found to be -1.36-fold of that of control 3T3-L1 cells as shown 
in Fig. 3.4.5.2. 
BBR- Ctrl 
treated 
SAPKy'JNK ^ J J ^ ^ j J j ^ 
Phospho- L : . . . . 丄 . : . . . . . . - ^ 一 
SAPK/JNK ^ ^ 2 ^ ^ ^ ™ f ^^ ^^ ^^ ^^ ^^  ^^ W^IWiWBPI^  
. . • � • ” . ‘ Fig. 3.4.5.2_Berberine treatment inhibited SAPK7JNK activity in mature 3T3-L1 adipocytes. 
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To investigate whether the berberine induced AMPK activation is due to increased 
adiponectin secretion from the cells, adiponectin was detected. However, berberine 
treatment resulted in no significant change in the level of adiponectin in mature 3T3-
L1 adipocytes. Protein disulphide isomerase (PDI), which was up-regulated by 
berberine in 2-DE, was also detected for confirmation. Level of PDI in BBR-treated 
cells was 1.8-fold higher than that in control cells. P-actin was detected as control. 
Fig. 3.4.5.3 shows the photos of the westem blot of these 3 proteins. 
BBR- Ctrl 
treated 
Adiponectin | g | | | g ^ | g j j ^ ¾^^ ?^^  "^¾^ ^^ !^ . PDI ，丨麵 M B l HiUk . r^ 5^W^^^^^^ ^^ lR|B^ ^^  P_actin ^^^^^^^^^^^ ^^ j^ ^^ T^^ I^UPPW^^^  
Fig. 3.4.5.3 Berberine treatment increased PDI expression but did not alter the 
expression of adiponectin in mature 3T3-L1 adipocytes. 
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4. Discussion 
4.1 Comparison of total protein profiles of visceral adipose tissue 
of obese db/db and lean m+/db mice 
All four proteins involved in glycolysis with differential abundance were upregulated 
in visceral adipose tissues (VAT) of obese db/db mice, including pyruvate kinase M, 
glucose phosphate isomerase 1，triosephosphate isomerase 1 and enolase 1，alpha 
non-neuron, indicating an increase in the rate of glycolysis. The down-regulation of 
proteins involved in TCA cycle and oxidative phosphorylation, including isocitrate 
dehydrogenase [NADP], mitochondrial precursor, iron response element binding 
protein, malate dehydrogenase, pyruvate carboxylase, NADH dehydrogenase 
(ubiquinone) Fe-S protein 1 and electron transfer flavoprotein-ubiquinone 
oxidoreductase, suggested an inhibition of TCA cycle and oxidative phoshorylation. 
The increased abundance of glycolytic proteins went along with the increase in 
expression of glycolysis enzyme encoding genes in human adipose tissues of obese 
patients (Baranova et al., 2005). The enhancement of glycolysis and the inhibition of 
TCA cycle and oxidative phosphorylation could be caused by the hypoxic conditions 
of adipose tissues in obese state as hypoxia can inhibit mitochondria respiration and 
biogenesis (Ye, 2009). Adipose tissue hypoxia could be caused by reduction in 
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adipose tissue blood flow in obesity (Karpe et al., 2002) and increase in adipocyte 
size. A large adipocyte can be over 150fxm, far beyond the interstitial oxygen 
diffusion limit of about 120pm The pyruvate produced should have undergone 
anaerobic respiration. It was reported that in adipose tissue of obese mice, the lactate 
concentration was 1.7-fold higher than that of lean control mice (Hosogai et al., 
2007). Sorbitol dehydrogenase was also significantly down-regulated. It is a 
mitochondrial protein involved in the polyol pathway, catalyzing the conversion of 
sorbitol to fructose. Accumulation of sorbitol is known to contribute to various 
diabetic complications such as cataract and diabetic neuropathay (Chung et al., 2003). 
Two enzymes involved in lipolysis, carboxylesterase 3 (also known as triglycerol 
hydrolase) and lipase, hormone sensitive isoform 2，were also down-regulated in 
VAT ofdb/db mice. This indicates a reduction in the rate of lipolysis, which may be 
accounted for the large adipocyte size in obesity. A recent study reported that the 
expression ofhormone sensitive lipase was down-regulated in both subcutaneous and 
omental fat depot of obese women (Ray et al., 2009). Two enzymes involved in beta-
oxidation were also altered. Acyl-Coenzyme A dehydrogenase, medium chain was 
up-regulated while enoyl Coenzyme A hydratase was down-regulated. However, 
reduced expression of other enzymes involved in beta-oxidation was detected by 
microarray in omental adipocytes isolated from obese patients (Walewski et al., 
2009)，suggesting a reduction in the rate ofbeta-oxidation in adipose tissues in obese 
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states. The inhibition of both lipolysis and beta-oxiation suggest a possible loss of 
lipid turnover in VAT of obese db/db mice, which could be causally linked to ectopic 
fat storage causing fatty liver of db/db mice. Up-regulation ofannexin A1 (ANAX1) 
was also detected in VAT of db/db mice. Beside its more well-known anti-
inflammatory property, annexin A1 was recently reported to regulate adipose tissue 
mass and IL-6 release (Wame et al., 2006). A significant reduction ofepididymal fat 
mass without significant change in mean adipocyte size was observed in ANAX1-
null mice, reflecting a reduction in adipocyte cell number. This suggested the role of 
annexin A1 in adipogenesis and regulation of adipocyte cell number. Glycerol and 
IL-6 release were also lowered in adipocytes isolated from ANAXl-null mice. The 
up-regulation of annexin A1 in VAT of db/db mice may explain the obesity and 
adiposity of the mice. 
Stress-related proteins were also altered. Superoxide dismutase 1 and carbonic 
anhydrase 3 were down-regulated (both >2-fold) while phospholipid hydroperoxide 
glutathione peroxidase and peroxiredoxin 1 were up-regulated (1.67-fold and 1.84-
fold respectively). The reduction of superoxide dismutase 1，an important anti-
oxidant in cells, and carbonic anhydrase 3 may indicate the oxidative stress in VAT 
of obese db/db mice. Phospholipid hydroperoxide glutathione peroxidase catalyzes 
the conversion ofglutathione and lipid hydroperoxide to glutathione disulphide, lipid 
and water, protecting the cells from lipid peroxidation. Besides, the reduction of 
77 
transferrin (-1.56-fold), which is involved in iron transport and metabolism, may 
affect cellular iron balance and cause oxidative stress. 
4.2 Berberine lowers body weight, reduces fasting blood glucose 
level and improves glucose-lowering ability of db/db mice 
After 49 days of treatment, body weight of the BBR-treated db/db mice was reduced 
by 25.33%+2.93% whereas body weight of water-treated control decreased by 
14.00%+3.75% only (p<0.05). Average fasting blood glucose level ofcontrol db/db 
mice was 466.83±38.34 mg/dL and that of BBR-treated mice was 266.80+36.07 
mg/dL whereas 2h-post-load glucose level in glucose tolerance test of control db/db 
mice was 567.43±31.53 mg/dL and that of BBR-treated mice was 466.60+53.36 
mg/dL. The significant body weight reduction ofBBR-treated mice should be due to 
reduction of fat mass, which was shown by computer tomography in BBR-treated 
db/db mice performed by another group (Lee et al., 2006). Milder reduction ofbody 
weight was also observed in control group. This may be an unintentional weight loss 
observed in patients with severe diabetes. This undesirable unintentional weight loss 
may be due to dehydration resulting from frequent urination or muscle breakdown 
under hyperglycemia. The reduction of fasting blood glucose level indicates an 
improvement in hepatic homeostasis as circulatory glucose after overnight fasting 
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mainly comes from hepatic glucose production. The lower 2h-post-load glucose level 
in BBR-treated db/db mice also indicates an improved glucose-lowering ability. 
4.3 Comparison of the protem profiles of visceral adipose tissue of 
BBR-treated and control db/db mice 
After BBR treatment, several but one proteins involved in glycolysis were up-
regulated in VAT of db/db mice, including triosephosphate isomerase, aldolase A, 
glyceraldehyde-3-phosphate dehydrogenase, enolase and pyruvate kinase. This 
indicates an up-regulation in glycolysis. For TCA cycle, two enzymes, citrate 
synthase and malate dehydrogenase 2，were down-regulated whereas ftimarate 
hydratase was up-regulated. This indicates an up-regulation in glycolysis and down-
regulation in TCA cycle. Increase in glycolysis can be resulted from AMPK 
activation, which stimulates energy providing pathways like glycolysis, glucose 
uptake and beta-oxidation (Viollet et al, 2009). Induction of glycolysis and 
activation of AMPK in adipocytes by berberine was also reported previously (Yin et 
al., 2008a; Lee et al.，2006). The down-regulation ofTCA cycle could also be due to 
mitochondrial inhibitory effect ofAMPK activation. 
BBR treatment also led to decrease of glucose-6-phosphate dehydrogenase level. 
Glucose-6-phosphate dehydrogenase is the rate-limiting enzyme in the pentose 
phosphate pathway. It converts glucose-6-phosphate to 6-phosphogluconolactone 
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with the concomitant production ofNADPH+H+. The NADPH+H+ produced during 
this reaction provides 50-75% reducing equivalents necessary for fatty acid 
biosynthesis in liver. Thus, glucose-6-phosphate dehydrogenase is also regarded as a 
lipogenic enzyme. It was recently reported that the inhibition of glucose-6-phosphate 
dehydrogenase in hepatocytes by arachidonic acid involves activation ofboth AMPK 
and p38 MAPK (Kohan et al., 2009). The inhibition of glucose-6-phosphate 
dehydrogenase in VAT of BBR-treated db/db mice may also be due to AMPK 
activation and/or p38 MAPK activation. 
Sorbitol dehydrogenase level, which decreased in adipose tissue of db/db mice 
compared to lean m+/db mice, increased after BBR treatment. This may alleviate the 
accumulation of sorbitol, which is associated with various diabetic complications. 
Aldo-keto reductase family 1，member A4, also known as aldehyde reductase or 
aldose reductase (AR), was also up-regulated. The role of AR is quite controversial. 
AR is also involved in the polyol pathway by converting aldehyde form of glucose 
into sorbitol together with the conversion of NADPH+H+ to NADP+. Sorbitol 
produced is then converted to fructose, a more effective glycating agent than glucose, 
by sorbitol dehydrogenase. The involvement of the polyol pathway in oxidative 
stress and diabetic complications makes inhibition of AR a potential therapeutic 
strategy against diabetic complications (Corso et al., 2008). However, AR also plays 
a role in detoxification of various toxic aldehydes (Kang et al., 2007). It was shown 
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that the up-regulation of AR via phosphatidylinositol 3-kinase/Akt (PI3K/Akt) 
pathway by curcumin, a polyphenolic antioxidant, is necessary for the cytoprotective 
effect of the polyphenolic compound (Kang et al., 2007). Up-regulation of AR may 
also contribute to inhibition of fatty acid biosynthesis by depletion ofNADPH+H+. 
Galectin-3 (Gal-3) level was also lowered after BBR treatment. This lectin is 
involved in a wide variety of biological activities such as cell adhesion, induction of 
pre-mRNA splicing, regulation of apoptosis, modulation of inflammation and cell 
proliferation (Kiwaki et al., 2007). It was recently found that Gal-3-null mice are less 
susceptible to streptozotocin-induced diabetes (Mensah-Brown et al., 2009). 
Macrophages infiltrated into the pancreas produced less TNF-a and nitric oxide in 
Gal-3-null mice and thus protecting the mice from immune-mediated beta cell 
damage. It was also found that galectin-3 stimulates human primary preadipocyte 
proliferation and up-regulation of galectin-3 was associated with growth of adipose 
tissue induced by high-fat diet in mice (Kiwaki et al., 2007). However, the role of 
galectin-3 in adiposity and obesity is still unknown. In this project, we found that a 
decrease in galectin-3 level was associated with body weight loss and reduced FBG 
in BBR-treated db/db mice, supporting the relationship between galectin-3 level and 
adiposity. 
Proteins involved in beta-oxidation, including acyl-Coenzyme A dehydrogenase 
(medium chain), long-chain specific acyl-CoA dehydrogenase, acyl-Coenzyme A 
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dehydrogenase (short chain) were all up-regulated after BBR treatment. This 
indicates an increase in the rate of beta-oxidation, which should be due to the 
activation of AMPK by berberine. Long-chain-fatty-acid-CoA ligase 1，also known 
as long chain fatty acyl-CoA synthetase, catalyzes the activation of a long fatty acid 
chain to a fatty acyl-CoA. Activation of fatty acid by esterification to fatty acyl-CoA 
is required before further utilization, usually beta-oxidation or lipid synthesis (Digel 
et al., 2009). Recent report stated that suppression of long chain acyl-CoA synthetase 
3 in hepatocytes lowered de novo fatty acid synthesis (Bu et al., 2009). Up-regulation 
of long chain fatty acid CoA ligase 1 by berberine may enhance activation of fatty 
acids and help reduce the amount of free fatty acids released from VAT. Whether the 
activated fatty acyl CoA would undergo beta-oxidation or lipid synthesis and 
whether the up-regulation of the fatty acyl CoA synthetase could inhibit de novo 
fatty acid synthesis in VAT is still uncertain. Carboxylesterase 3，which was down-
regulated in VAT of db/db mice compared with that of m+/db mice, was up-
regulated after BBR treatment. Though lipolysis should have been inhibited by 
AMPK activation, the up-regulation of carboxylesterase 3，a lipolytic enzyme, may 
just restore its level back to normal and allow a normal tumover of lipids, fatty acids 
and glycerol in the adipocytes. Glycerol-3-phosphate dehydrogenase 1 (soluble) was 
also up-regulated. It catalyzes the reduction of dihydroxyacetone phosphate into 
glycerol-3-phosphate together with the conversion of NADH+H+ to NAD+. Several 
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compounds or plant extracts ameliorating lipid accumulation or dyslipidaemia were 
shown to reduce glycerol-3-phosphate dehydrogenase activity (Kim et al., 2009; Lee 
et al., 2009; Kubota et al., 2009). Up-regulation of glycerol-3-phosphate by berberine 
may contribute to the recycling ofNAD+required for the enhanced glycolysis. 
Two stress-related proteins were up-regulated. Carbonic anhydrase 3，which was 
down-regulated in VAT of obese db/db mice compared with that of m+/db mice, was 
up-regulated by berberine. Calreticulin, a multifunctional Ca:+ buffering molecular 
chaperone and modulator of gene expression (Michalak et al., 2009), was also up-
regulated. Recent study found that adipogenesis is promoted in calreticulin-deficient 
embryonic stem cells. Overexpression of [P+C] domain, which is responsible for the 
Ca2+ buffering function, of calreticulin in 3T3-L1 preadipocytes also inhibits lipid 
accumulation (Szabo et al., 2008), indicating the effect of Ca^^ content modulation in 
adipogenesis. The up-regulation of calreticulin by berberine may play a role in 
inhibition of adipogenesis in VAT of db/db mice. However, it may also indicate 
presence of stress in endoplasmic reticulum. 
Mitogen activated protein kinase 1 (MAPK1), also known as extracellular signal-
regulated kinase 2 (ERK2), was up-regulated by berberine. This protein is known to 
be involved in the control of cell proliferation and it was recently reported that it is 
involved in lipid droplet formation (Bostr6m et al., 2009). 
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4.4 Berberine inhibited lipid accumulation in mature and pre-
mature 3T3-L1 adipocytes 
Prolonged berberine treatment (72h) at 5p,M reduced the intracellular accumulation 
of triglyceride in mature adipocytes by 31.9% whereas short-term berberine 
treatment (24h) at 5p,M reduced the intracellular accumulation of triglyceride in pre-
mature adipocytes by 17.5%. The reduction of triglyceride accumulated in mature 
adipocytes and inhibition of lipid accumulation in pre-mature, differentiating 
adipocytes may be accounted for the body weight loss in BBR-treated db/db mice. 
But the former one should have played a more important role in weight loss and the 
adipocytes in the obese db/db mice are mostly mature and overload with triglyceride. 
4.5 Berberine enhanced lipolysis in mature 3T3-L1 adipocytes but 
inhibited lipolysis in pre-mature 3T3-L1 adipocytes 
Prolonged (72h) berberine treatment at 5 i^M in mature 3T3-L1 adipocytes increased 
the glycerol concentration in culture media by 33% whereas short-term treatment 
(24h) reduced the glycerol concentration in culture media by almost 50%. It was 
previously reported that 18h-treatment of 5 i^M BBR in mature 3T3-L1 adipocytes 
could reduce glycerol secretion by 41% (Choi et al., 2006), similar to our short-term 
treatment results. Decrease in secreted glycerol level indicates inhibition of lipolysis 
by berberine, at least for short-term. The increase in secreted glycerol level after 
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prolonged berberine treatment may be attributed to the possible increase in beta-
oxidation induced by berberine, which may in tum drive lipolysis. For in vivo 
situation, it is speculated that an increase in lipolysis after long term daily BBR 
treatment is more likely to take place as the adipocytes in adult individuals are 
mostly mature and the treatment is usually long term. This is also supported by the 
loss of intracellular triglyceride accumulated in mature 3T3-L1 adipocytes shown in 
Oil Red 0 staining. The loss of triglyceride already accumulated in the mature 
adipocytes should be due to an increase in lipolysis. 
4.6 Comparison of the protein profiles of BBR-treated and control 
3T3-L1 adipocytes 
Glycolytic enzyme, aldolase A, which catalyzes the conversion of fructose 1,6-
bisphosphate into glyceraldehyde-3 -phosphate and dihydroxyacetone phosphate, was 
up-regulated after berberine treatment. This may indicate the enhancement of 
glycolysis by berberine, which was also reported previously (Yin et al., 2008a). 
Triosephsophate isomerase, unlike the result from BBR-treated db/db mice, was 
down-regulated. Triosephosphate isomerase is responsible for catalyzing the 
conversion of dihydroxyacetone phosphate into glyceraldehyde-3 -phosphate which 
proceeds in glycolytic processes. Down-regulation of this enzyme may lead to 
accumulation of dihydroxyacetone phosphate, which is the substrate for the up-
regulated glycerol-3-phosphate dehydrogenase. The conversion of dihydroxyacetone 
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phosphate to glycerol-3-phosphate may therefore be enhanced. This may allow the 
recycling ofNAD+ from NADH+H+ for glycolysis. Enzymes involved in TCA cycle, 
including aconitase and isocitrate dehydrogenase, were down-regulated. This may be 
due to the mitochondrial inhibitory effect of AMPK activation induced by BBR. 
Citrate synthase and fumarate hydratase were, however, up-regulated. The up-
regulation of ftimarate hydratase was even found in both VAT of BBR-treated db/db 
mice and BBR-treated 3T3-L1 adipocytes. Fumarate can inhibit prolyl hydroxylase 
enzymes, which are responsible for degradation of hypoxia-inducible factors (HIFs), 
in cytosol (King et al., 2006). HIFs enhance glycolysis, angiogenesis and other 
mechanisms under hypoxic conditions for cell survival. Up-regulation of fumarate 
hydratase by berberine may prevent the accumulation of fumarate and alleviate the 
subsequent prolyl hydroxylase inhibition and thus enhance degradation of HIFs. 
Hence, the increase in glycolysis induced by berberine is not likely due to hypoxia in 
obesity, but should be due to AMPK activation. It was also reported that berberine 
can inhibit HIF-la expression via enhanced proteolysis in human gastric 
adenocarcinoma SC-M1 cell line (Lin et al., 2004). Galectin-3, which was down-
regulated in the VAT of BBR-treated db/db mice, was also down-regulated in BBR-
treated 3T3-L1 adipocytes. 
Down-regulation of acetyl-CoA acetyltransferase, which is responsible for formation 
of acetoacetyl-CoA and thus cholesterol synthesis, may help reduce cholesterol. 
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Carnitine 0-palmitoyltransferase, which is responsible for the transport of acyl-CoA 
from cytosol into mitochondrial matrix for beta-oxidation, was up-regulated. This 
may enhance beta-oxidation. There may be increase in lipolysis as indicated by the 
up-regulation of triacylglycerol hydrolase (carboxyesterase 3). Up-regulation of 
glycerol-3 -phosphate dehydrogenase may be responsible for providing the NAD+ 
required in enhanced glycolysis. Enhanced lipolysis, beta-oxidation and formation of 
glycerol-3 -phosphate (lipogenesis) may show that the cells have a better tumover of 
fatty acid and lipids and have gained a better elasticity for energy storage. 
Unexpectedly, several endoplasmic reticulum (ER) stress-related proteins were up-
regulated after BBR treatment, including heat shock protein 90 (HSP90), calreticulin 
and protein disulphide-isomerase (PDI). HSP90 is a molecular chaperone for the 
folding, stabilization, activation and assembly of other "client" proteins. Calreticulin 
is another stress-induced molecular chaperone with Ca?+ buffering action. Up-
regulation of calreticulin may also inhibit lipid accumulation and adiogenesis as 
mentioned above. PDI is involved in unfolded protein response (UPR). As ER stress 
is positively associated with diabetes and obesity and administration of chaperones 
that block ER stress activation could to reverse insulin resistance (Ozawa et al., 
2005; Ozcan et al., 2006), the up-regulation ofUPR- and ER stress-related proteins is 
quite unexpected. However, a recent study states that berberine can induce G2/M 
arrest and apoptosis in C6 rat glioma cells in an ER-dependent manner, with an 
87 
increase in level of glucose-regulated protein 78, a regulator of UPR. Production of 
reactive oxygen species is also promoted (Chen et al., 2009). This may explain the 
down-regulation of superoxide dismutase. 
Trimethyllysine 2-oxoglutarate dioxygenase is involved in lysine degradation and 
carnitine biosynthesis. It catalyzes the conversion of trimethyllysine to 3-hydroxy-
trimethyllysine, together with the conversion of a-ketoglutarate to succinate. 
Succinate, like fumarate as mentioned above, can inhibit prolyl hydroxylase 
enzymes, which are responsible for degradation of hypoxia-inducible factors (HIFs), 
in cytosol (King et al., 2006). Down-regulation of trimethyllysine 2-oxoglutarate 
dioxygenase by berberine treatment may prevent succinate accumulation and thus 
ameliorate hypoxia-induced cellular responses. 
4.7 Western blotting 
Level of phospho-AMPK-alpha (Thrl72) of BBR-treated 3T3-L1 was 2.37-fold of 
that of control cells. This confirmed that berberine enhanced AMPK activity in 3T3-
L1 adipocytes as previously reported by others (Lee et al., 2006; Yin et al., 2008a). 
However, this AMPK activation was not due to increased adiponectin secretion as 
level of adiponectin did not alter significantly after berberine treatment. 
Level of phospho-SAPK/JNK (Thrl83/Tyrl85) ofBBR-treated 3T3-L1 was found to 
be -1.36-fold of that of control cells, revealing that berberine inhibited JNK activity 
in 3T3-L1 adipocytes. As JNK leads to serine phosphorylation ofIRS-1 and impairs 
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the insulin signaling pathway which involves the activation of phosphatidylinositol 
3-kinase (PI3K pathway) and MAP kinase pathway, inhibition of JNK activity may 
be another mechanism for the anti-diabetic effect and inhibition of lipid 
accumulation of berberine. Although Kim et al. reported that berberine does not 
affect insulin-responsive signal transduction pathway (Kim et al., 2007)，they just 
showed that berberine does not augment tyrosine phosphorylation of IRS-1 and 
effect ofberberine on 3T3-L1 is not via PI3K pathway. 
Increased expression of PDI after berberine treatment observed in 2-DE was 
confirmed in westem blotting. This suggested that berberine might cause ER stress in 
3T3-L1 adipocytes. 
4.8 General discussion 
Berberine treatment lowered body weight and fasting blood glucose level of obese, 
diabetic db/db mice. It also improved glucose-lowering ability of db/db mice in 
glucose tolerance test. The reduction of body weight may be due to reduction of 
triglyceride accumulation in adipose tissues of the mice. In vitro study showed that 
both short-term (24h) and prolonged (72h) treatment of berberine could reduce 
triglyceride accumulation in 3T3-L1 adipocytes. 
Proteomic study of VAT of BBR-treated db/db mice and BBR-treated 3T3-L1 
adipocytes suggested there was increase in glycolysis, lipolysis and beta-oxidation 
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but also inhibition of TCA cycle and oxidative phosphorylation. The increase in 
glycolysis and beta-oxidation as well as the inhibition of TCA cycle and oxidation 
phosphorylation should be owing to activation of AMPK by berberine. But AMPK 
activation does not enhance lipolysis. Increased expression of glycerol-3-phosphate 
dehydrogenase in both VAT of BBR-treated db/db mice and BBR-treated 3T3-L1 
adipocytes also hinted an increase of glycerol-3-phosphate level in the adipocytes, 
suggesting a possible restoration of a "healthy" turnover of fatty acids and 
triglyceride in the adipocytes. Similar proteomic changes in these metabolic 
pathways in both in vivo and in vitro model suggested that the proteomic changes in 
the visceral adipose tissue of BBR-treated db/db mice were largely due to direct drug 
action but not mainly due to the metabolic alterations produced by the drug action. 
Westem blotting showed that berberine inhibited SAPK/JNK in 3T3-L1 adipocytes. 
It was recently reported that silencing of JNK1 accelerates basal lipolysis as well as 
enhances re-esterification of fatty acids in 3T3-L1 (Rozo et al., 2008). Therefore, the 
increased expression of carboxyesterase 3 and triglycerol hydrolase, in 2-DE of 
BBR-treated VAT of db/db mice and BBR-treated 3T3-L1 adipocytes respectively, 
may be due to JNK inhibition. The link of berberine to JNK pathway may worth 
further investigation. 
The association between ER stress and obesity has been supported in this decade. 
Berberine treatment, unexpectedly, increased PDI level in both VAT of db/db mice 
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and 3T3-L1 adipocytes, suggesting that berberine might enhance ER stress in 
adipocytes. 
Though generally regarded as an anti-oxidant, berberine did not increase the 
expression of many anti-oxidizing proteins or ROS scavengers in 2-DE. However, 
the increased expression of fumarate hydratase in both VAT of db/db mice and 3T3-
L1 adipocytes and the decreased expression of trimethyllysine 2-oxoglutarate 
dioxygenase hinted possible inhibition of HIFs and amelioration of hypoxic 
conditions in adipocytes. But fiirther experiments will be needed for confirmation. 
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